The use of MALDI-MS for imaging drug disposition in respiratory disease models. by Flinders, Bryn.
The use of MALDI-MS for imaging drug disposition in 
respiratory disease models.
FLINDERS, Bryn.
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/19652/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
FLINDERS, Bryn. (2013). The use of MALDI-MS for imaging drug disposition in 
respiratory disease models. Doctoral, Sheffield Hallam University (United Kingdom).. 
Copyright and re-use policy
See http://shura.shu.ac.uk/information.html
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
| uttwnipy ar«o -wonT.-ation services 
| Adsetta Centra, City Campus 
j Sheffield SI 1WD
1 0 2  0 1 9  7 8 0  3
 ^ Sheffield Hallam University
Lea? rung and information Services 
Mosecs Centre. City Campus 
Sheffield S1 1WB
r e f e r e n c e
ProQuest Number: 10694533
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com ple te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10694533
Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
The use of MALDI-MS for imaging drug disposition in 
respiratory disease models.
Bryn Flinders
A thesis submitted in partial fulfilment of the requirements of Sheffield Hallam 
University for the degree of Doctor of Philosophy
September 2013
Acknowledgements
First and foremost I would like to thank my supervisor Professor Malcolm 
Clench, for giving me the opportunity to undertake this project and for his help 
and support.
This PhD was supported by a MRC case studentship in collaboration with 
GlaxoSmithKline and Sheffield Hallam University.
I would like to thank my industrial supervisors Josie Morrell, Dr Peter Marshall 
and Lisa Ranshaw from GlaxoSmithKline (Stevenage) for their support 
throughout this project.
Also I would like to thank Dr Simona Francese and Dr Akram Khan for their help 
and advice.
I would also like to thank members of the mass spectrometry group at Sheffield 
Hallam University, many thanks to Dr Paul Trim, Laura Cole, Leesa Ferguson, 
Dr Marie-Claude Djidja, Dr Philippa Hart, Dr Jill Newton, Christopher Mitchell, 
Robert Bradshaw and Afnan Baturba for their friendship, help and support 
throughout.
I would also like to take this opportunity to thank Dr Andrew McEwen from 
Quotient Bioresearch Ltd for his permission to use some of the WBA data in this 
thesis.
Also I would like to thank Professor Ron Heeren and Ivo Klinkert from FOM 
Institute AMOLF for their permission and help to use the Volume Explorer 
software to generate data included in this thesis.
Last but not least I would like to thank my parents for their love, encouragement 
and support over the last three years.
Abstract
Matrix-assisted laser desorption/ionisation-mass spectrometry imaging (MALDI- 
MSI) has been extensively applied to monitoring the distribution of 
pharmaceutical compounds in tissues. The main aim of the work reported in this 
thesis is to monitor the distribution of respiratory compounds in the lungs 
following inhaled delivery.
Glucocorticoids that contain multiple carbonyl functionalities are not easily 
protonated/de-protonated to form charged species due to the poor ionisation 
efficiencies of the carbonyl functionalities. Derivatisation with hydrazine based 
reagents has been proposed as a solution to this problem. These reagents have 
been employed for the in-solution and on-tissue derivatisation of a range of 
glucocorticoids to form their respective hydrazones improving their mass 
spectral ionisation efficiency and detection.
MALDI-MSI has been used to screen a set of respiratory compounds in order to 
determine their on-tissue limit of detection. The distribution of a Tiotropium 
Bromide was monitored throughout the lungs following inhaled delivery. High 
spatial resolution imaging enabled a detailed view of the distribution of 
Tiotropium in the trachea and major airways.
Quantitative mass spectrometry imaging is a new field that has recently gained 
a lot of attention especially in pharmaceutical research. The ability to obtain 
quantitative information as well as the distribution of pharmaceutical compounds 
and associated metabolites offers a distinct advantage over traditional 
quantitative methods such as LC-MS/MS and QWBA. The current methods of 
generating quantification information from MALDI-MS images has been 
evaluated, which let development of a method for the preparation of standards 
for use in the quantification of drugs in tissue sections.
MALDI-MSI has been used to acquire data from serial sections obtained at 
equal intervals through control mouse lung tissue, homogenate registration 
markers were incorporated in order to aid the final 3D image construction. Using 
two 3D imaging software packages were used to reconstruct the images were 
stacked together to enable the 3D distribution of a particular endogenous 
species throughout the lungs to be displayed.
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1.1: Introduction to respiratory conditions 
1.1.1: Asthma
Asthma is a chronic inflammatory disease which may be caused by exposure to 
environmental allergens. Asthma is characterised by intermittent and variable 
airflow obstruction and airway hyper-responsiveness to allergens. This leads to 
wheezing, breathlessness, coughing and chest tightness. These symptoms are 
reversed with treatment (Caramori and Adcock 2003). Airflow obstruction can 
be caused by several factors e.g. vasodilatation, increased luminal secretion or 
smooth muscle contractions which can cause bronchospasms (Baker and Lai 
2008).
1.1.1.1: Burden of asthma
According to the World Health Organisation (WHO), in 2011 approximately 300 
million people suffered from asthma and it claimed the lives of 255,000 people 
worldwide (www.who.int). Asthma UK estimates that there are currently 5.4 
million people in the United Kingdom that have asthma (www.asthma.orq.uk). 
Asthma is more prevalent in developed countries (such as the United Kingdom 
and the United States). However, asthma is becoming increasingly prevalent in 
developing countries (such as South America and Asia) due to increased 
urbanization and the adoption of western lifestyles (Braman 2006). This is 
illustrated in the diagram shown in Figure 1.1.
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Figure 1.1: Map showing the global prevalence o f clinical asthma (Masoli et a!., 
2004).
1.1.1.2: Causes of asthma
There are many factors that are associated with the development of asthma, it 
is thought that in the case of genetically susceptible people if they are exposed 
to a particular allegen during a point in their life (usually childhood) this results 
in the production of immunoglobulin-E (IgE). It is upon re-exposure to that 
particular allergen that the person will present with the symptoms of asthma 
(Bourke 2007).
There have been many environmental factors that have been associated with 
the development of asthma, people that live in modern, urban and economically 
developed societies such as western parts of the world or countries that have 
adopted western culture are likely to develop asthma.
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Other environmental factors can be separated into two groups:
• Outdoor environmental allergens - it is thought that atmospheric pollution 
such as vehicle exhaust emissions can trigger an asthmatic episode, 
however the most common outdoor allergens are pollen and fungal spores 
(Bourke 2007).
• Indoor environmental allergens -  people tend to spend most of their time 
indoors and hence are greatly exposed to allergens that are derived from 
pets (such as fur or flakes of skin) and house dust mites (Barker and Lai 
2008).
There are other factors that play a part in the development of asthma: 
respiratory infections like influenza can increase airway responsiveness in 
people, smoking can increase the production of IgE, diet such as eggs or milk 
can result in an asthmatic episode and drugs such as aspirin can induce 
bronchoconstriction (Barker and Lai 2008, Bourke 2007).
1.1.1.3: Pathogenesis of asthma
An asthmatic attack /episode starts by the inhalation of an allergen (early phase 
reaction) to which the subject has become sensitized, the allergen interacts with 
the IgE antibody that has bound to the receptors of inflammatory cells (such as 
mast cells). This results in the activation of the inflammatory cells which 
degranulate and release mediators (such as histamine, prostaglandins and 
leukotrienes) this then results in smooth muscle contraction, increased luminal 
secretions and increased vascular permeability resulting in mucosal oedema 
(Bourke 2007), as shown in Figure 1.2.
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Figure 1.2: Diagram showing the difference between normal lung tissue and 
that following an asthmatic episode (www. nhlbi. nih.gov).
The inflammatory response (late phase reaction) of asthma is mediated through 
T-helper lymphocytes commonly Th2 cells, which produce cytokines and up- 
regulate the production of IgE and eosinophil and mast cell function (Bourke 
2007). Once activated T cells attract eosinophils which release tissue damaging 
proteins and leukotrienes, which results in mucus hypersecretion, mucosal 
odema and bronchospasm (Baker and Lai 2008).
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1.1.2: Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) clinically describes chronic 
bronchitis and emphysema two co-existing diseases that cause progressive and 
irreversible damage to the lungs. COPD is a disabling condition with symptoms 
that progress gradually, leading to breathlessness, wheezing, excess coughing 
and sputum production. At present there is no cure and non-pharmacological 
/pharmacological treatments merely alleviate symptoms and slow the 
progression of the disease.
1.1.2.1: Burden of COPD
According to the World Health Organisation (WHO) in 2011 approximately 210 
million people had COPD. The disease claimed the lives of more than 3 million 
people in 2011, which was equal to 5 % of all the deaths globally that year. 
COPD is currently the fourth leading cause of death worldwide, however based 
on current trends it is estimated that by 2030 chronic obstructive pulmonary 
disease will be the third leading cause of death worldwide (www.who.int).
1.1.2.2: Causes of COPD
Cigarette smoking is the main cause of COPD, however only 15% of smokers 
develop COPD indicating that additional factors have an influence on the 
development of COPD (Maskell and Miller 2009). The additional factors that 
have been identified include: vehicle exhaust fumes and occupational exposure 
to dust or fumes from coal mining, paint spraying, cotton processing and 
farming. These factors all contribute to a reduced forced expiratory volume 
(FEV-i) and an increased risk of developing COPD (Bourke 2007).
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An imbalance between proteases and anti-proteases can be the result of a 
genetic deficiency in the anti-proteases such as a1-antitrypsin, which accounts 
for 2 % of COPD cases (Maskell and Millar 2009). Normally there is a balance 
between proteases and antiproteases, however a deficiency in anti-proteases 
could lead to the development of emphysema early on in life (Bourke 2007).
Also an imbalance between oxidants and anti-oxidants can be the result of 
cigarette smoke and air pollution which both contain unstable reactive oxygen 
species. Oxidants are also endogenously produced by neutrophils and 
macrophages during the inflammatory response. Oxidants cause damage to 
anti-proteases, increase mucus secretion and activate transcription factors that 
produce pro-inflammatory mediators (Hansel and Barnes 2004, Maskell and 
Millar 2009).
1.1.2.3: Pathogenesis of COPD
Briefly COPD is commonly caused by long term exposure to cigarette smoke, 
COPD is characterised by airway inflammation/scarring and increased luminal 
mucus secretion (chronic bronchitis) and destruction of the lung parenchyma 
(emphysema) resulting in a loss in lung elasticity and elastic recoil, resulting in a 
reduced airflow which is not fully reversible (Baker and Lai 2008). This is 
illustrated in Figure 1.3.
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Figure 1.3: Diagram showing the difference between normal lung tissue and 
that afflicted with Chronic Obstructive Pulmonary Disease (www.nhlbi.nih.gov).
The inflammation mechanism in COPD is complex and is illustrated in Figure 
1.4, it is thought that cigarette smoke or other inhaled irritants induce an 
inflammatory response in the respiratory epithelium and lung parenchyma. 
Macrophages, epithelial cells and CD8-T lymphocytes are stimulated to release 
neutrophil chemotaxins such as interleukin-8 (IL-8) and leukotriene-B4 (LTB4). 
Macrophages can cause damage directly by releasing proteases and indirectly 
by release of chemicals called cytokines that attract neutrophils; cytokines alter 
the permeability of the blood vessel walls, attracting neutrophils that pass 
through the blood vessel wall to the site of inflammation, in addition fluid leaks 
from blood into the surrounding tissue causing them to become oedematous 
and swollen (Maskell and Millar 2009, Hansel and Barnes 2004).
Neutrophils also release proteases that begin to break down the parenchyma 
(emphysema) and promote mucus hypersecretion (chronic bronchitis).
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Figure 1.4: Scheme showing the inflammation mechanism o f COPD (Image 
adapted from Barnes and Hansel 2004).
Mucus hypersecretion is characteristic of chronic bronchitis. Cigarette smoke 
and other inhaled irritants result in mucus production through reflex activation of 
sensory nerves, however as the process becomes chronic there is an increased 
amount of goblet cells, enlargement of submucosal bronchial glands and 
thickened smooth muscle resulting in excessive coughing.
Emphysema is characterised by enlargement of the airspaces and destruction 
of the lung parenchyma resulting in the production of large holes or bullae 
resulting in gas exchange abnormalities. This is illustrated in Figure 1.5, which 
shows computerised tomography (CT) scans of a cross-section of healthy lungs 
and emphysematous lungs.
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Figure 1.5: Computed tomography (CT) scans showing the cross-section o f 
healthy lungs on the left and emphysematous lungs on the right (Barker and Lai 
2008).
The healthy lung cross-section shows the lung tissue as a heterogenous grey 
colour and the structure of the lungs is rounded and even. In comparison with 
that of the emphysematous lung which shows black staining from carbon 
deposits caused by cigarette smoke and air pollution, also the lungs have large 
holes also known as bullae caused by proteolysis of the lung parenchyma 
(indicated by the red arrow). The emphysematous lungs also show the lungs 
are not rounded and even meaning a loss in elastic recoil resulting in a difficulty 
to breathe (Barker and Lai 2008, Bourke 2007).
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1.2: Pharmaceutical treatment strategies 
1.2 .1 : 69-adrenoreceptor agonists 
1 .2 .1 .1 : B?-adrenoreceptor agonists target
The P2-adrenoreceptor is a single polypeptide glycoprotein complex that is 
embedded within the plasma membrane (Page and Barnes 2004). This receptor 
belongs to a seven-transmembrane domain family of receptors which are also 
known as G-protein coupled receptors (Johnson 2001). It is found in high 
concentrations throughout the respiratory tract and bronchial smooth muscle 
with approximately 30-40,000 receptors per cell (Sears and Lotvall 2005). G- 
protein coupled receptors are also found in the epithelium, in vascular smooth 
muscle and in submucosal glands. This could explain the regulation of mucus 
secretion observed following fc-adrenoreceptor agonist administration (Barnes 
2004b).
The P2-adrenoreceptor is composed of 413 amino acid residues that are 
arranged into seven-membrane spanning alpha helices with an extracellular N- 
teminus and an intracellular C-teminus and three intracellular loops (Clark et a/., 
1993, Sears and Lotvall 2005) as shown in Figure 1.6. These helices group 
together to form a hydrophobic binding site, which is accessible to compounds 
via the extracellular aqueous biophase (Anderson etal., 1994).
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Figure 1.6: Proposed structure o f the /32-adrenoreceptor which consists o f 
seven a-helices spanning the membrane, amino acid residues important in 
agonist binding are circled (Image adapted from Sears and Lotvall 2005).
1.2.1.2: Structures of 3?-adrenoreceptor agonists
Salbutamol (Figure 1.7A) is a short-acting (32-adrenoreceptor agonist that 
consists of the catechol nucleus (benzene ring with two hydroxyl groups at 
positions 3 and 4) and an amino side chain that is responsible for the direct 
interaction with the active site of the receptor. Formoterol (Figure 1.7B) is a 
long-acting (B2-adrenoreceptor agonist and is a formanilide substituted 
phenoethanolamine. Salmeterol (Figure 1.7C) is also a long-acting (32- 
adrenoreceptor agonist it is a saligenin derivative of phenylethanolamine 
(Anderson eta l., 1994).
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Figure 1.7: Structures of the (32-adrenoreceptor agonists A) salbutamol, B) 
formoterol and C)salmeterol.
The structures of the p2-adrenoreceptor agonists determine how they enter the 
active site of the P2-adrenoreceptor and the agonistic duration of action. The 
mechanism of interaction for each of the compounds described above is 
illustrated in Figure 1.8 .
Formoterol
Salmeterol
Aqueous biophase
Uptake
Membrane
translocationUpldbllayer 1 ■ *membrane
B -^adrenoreceptor
Figure 1.8: Diagram illustrating the different interactions of the three p2- 
adrenoreceptor agonists with the (32-adrenoreceptor (Johnson 2001).
Salbutamol is a hydrophilic compound and interacts directly with the active site 
of a p-adrenoreceptor, resulting in a rapid onset of action (Johnson 2001).
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Bronchodilation occurs within 2-3 minutes and peak bronchodilation is achieved 
at 15 minutes post inhalation. Salbutamol is however, only a short acting p2- 
adrenoreceptor agonist, as it only weakly binds to the active site of the receptor 
resulting in a duration of action of around 4-6 hours (Sears and Lotvall 2005). 
Another (32-adrenoreceptor agonist, formoterol is partially lipophilic and is taken 
up by the cell membrane to form a depot. From here the compound diffuses into 
the receptor and interacts with the active site and consequently has a prolonged 
duration of action of up to 12 hours (Sears and Lotvall 2005).
In contrast, salmetrol is highly lipophilic due to the long side-chain within the 
compounds structure and as a result it enters the cell membrane and laterally 
diffuses into the receptor, however this process is slow and can take up to 30 
minutes (Johnson 2001). The binding of salmeterol to the active site is a unique 
process that involves the binding of the side-chain to a secondary binding site 
called the “exo-site”. The saligenin head of the compound can freely engage 
and disengage from the active site due to the oxygen within the compound 
acting as a hinge or fulcrum. Whilst the onset of action is relatively slow this 
unique method by which salmeterol interacts with the active site of the receptor, 
enables a prolonged duration of action of up to 12 hours.
1.2.1.3: Mechanism of action
B2-adrenoreceptor agonists are used to stimulate bronchial smooth muscle 
relaxation through activation of adenyl cyclase (Baker and Lai 2008). Activation 
of adenyl cyclase is facilitated by the receptor-associated guanine nucleotide 
regulatory protein (Gs protein). This is composed of a, (3 and y subunits. In a 
resting state the a-subunit binds GDP and exists as a heterotrimer with the (3 
and y subunits (Johnson 2001). However on receptor activation the GDP is
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released allowing GTP to bind to the a-subunit, which dissociates from the (3 
and y subunits and interacts with adenyl cyclise that converts ATP into cAMP 
(Johnson and Druey 2002). Production of cAMP subsequently leads to the 
activation of cAMP-dependant protein kinase A (PKA), which then causes the 
inactivation (by phosphorylation) of myosin light chain kinase (MLCK). 
Inactivated MLCK precludes interaction with the contractile protein myosin, 
thereby promoting smooth muscle relaxation as shown in Figure 1.9 (Caramori 
and Adcock 2003). p2-adrenoreceptor agonists can also promote smooth 
muscle relaxation by activation of pathways which reduces Ca2+ levels, this 
causes a reduction of Ca2+ dependant actin-myosin leading to relaxation of 
smooth muscle within the airway (Caramori and Adcock 2003).
K~ channel 
openersyjv- p2"AdrenocePtor
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Figure 1.9: Diagram showing the effect o f Beta 2-Adrenergic receptor agonists 
on promoting smooth muscle relaxation (Adapted from Barnes 2004c).
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1.2.2: Corticosteroids
Corticosteroids (or glucocorticoids) are the mainstay of asthma management 
treatment and are commonly called preventers as these compounds treat the 
underlying disease process by reducing the number of inflammatory cells in the 
airways (such as eosinophils, T lymphocytes and mast cells) thus providing a 
resistance to severe attacks. Corticosteroids are also used in the treatment of 
COPD (Calverley 2000), however because of the damage caused by the 
disease to the lungs their anti-inflammatory effect is minimal and barely 
increases the patients forced expiratory volume (Baker and Lai 2008).
1.2.2.1: Structures of corticosteroids
All modern corticosteroids used in the management of asthma are synthetic 
analogues of natural corticosteroids such as cortisone and hydrocortisone, first 
isolated from the adrenal glands in the late 1930’s and successfully used in anti­
inflammatory treatment in the mid 1940’s (Gupta etal., 2004).
Structural modifications by way of the addition or modifications of various 
functional groups helped to improve the anti-inflammatory action and reduce 
some of the observed systemic side effects. Dexamethasone (Figure 1.10A) 
was introduced in the 1950’s and is derived from triamcinolone by the 
replacement of the 16a-hydroxyl group with a methyl group, this further 
improved the anti-inflammatory action and devoid of any side effects.
The major breakthrough came with the inhalation of topically active 
corticosteroids for the management of asthma, which negates any associated 
systemic side effects. Beclomethasone dipropionate (Figure 1.10B) which is a 
derivative of beclomethasone, was one of the first of inhaled topically active 
corticosteroids. Fluticasone propionate (Figure 1.10C) is a derivative of
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fluticasone. Budesonide (Figure 1.1 OD) introduced in early 1980’s is a non- 
halogenated corticosteroid.
The role of particular functional groups and the history of the production of 
modern synthetic corticosteroids were reviewed by (Gupta etal., 2004).
Figure 1.10: Structures of the synthetic corticosteroids A) dexamethasone, B) 
beclomethasone dipropionate, C) fluticasone propionate and D) budesonide.
1.2.2.2: Mechanism of action
Corticosteroids illicit an anti-inflammatory responce by crossing the cell 
membrane and binding to the intracellular glucocorticoid receptor (GR) as 
shown in the schematic in Figure 1.11. In their dormant state glucocorticoid 
receptors are bound in an oligomeric complex to chaperone proteins such as 
the 90 KDa heat shock protein (hsp90). This prevents the receptor from moving 
into the nucleus (Pelaia etal., 2003).
The binding of the corticosteroid to the C-terminal end of the dormant 
glucocorticod receptor, results in allosteric changes to the structure of the 
receptors causing the chaperone proteins to detach. The loss of the chaperone 
proteins reveals nuclear localisation signals on the glucocorticoid receptor and
C D
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allows the active steroid-receptor complex to translocate into the nucleus (Page 
and Barnes 2004).
Once in the nucleus the activated steroid-receptor complex can homodimerise 
and bind to the "glucocorticoid response elements" of the target DNA (Umland 
et a/., 2002). The binding is mediated through what are known as "zinc fingers" 
which consist of a zinc ion tetraedrically coordinated to four cystiene residues 
located on the glucocorticoid receptor (Barnes 1998).
GCS bindingTaut DNA binding „ 'Tau2
Z n )  (Zn
Tzatlon
Zinc fingers
Figure 1.11: Simplified structure of the glucocorticoid receptor, showing the 
corticosteroid binding domain at the C-terminal region of the receptor and the 
DNA binding domain in the middle of the receptor with the “zinc fingers” (Barnes 
1998).
This results in the unwinding of DNA and allows access of the CREB-binding 
protein (CBP), this forms a scaffold for the attachment of transcription factors 
and also has histone acetyl transferase (HAT) activity. Acetylation of histones 
permits unwinding of the local DNA and permits the RNA polymerase II to 
transcribe messenger RNA resulting in the production of anti-inflammatory 
proteins (Hansel and Barnes 2004). This increase in gene transcription of anti­
inflammatory proteins is known as transactivation (Barnes 2010).
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Corticosteroids can also exert their anti-inflammatory effect by blocking the 
transcription of pro-inflammatory mediators, which are activated by external 
stimuli. This process is known as transrepression (Barnes 2010). It involves the 
active steroid-receptor complex acting as a monomer which interacts with CBP, 
resulting in an inhibition of CBP-mediated histone acetyl transferase (HAT) 
activity thus preventing the unwinding of DNA and the production of pro- 
inflammatory mediators. In addition glucocorticoid receptors may also recruit 
histone deactylases (HDAC’s) to the CBP complex leading to tight nucleotide 
compaction and repression of the production of pro-inflammatory mediators 
(Hansel and Barnes 2004). The two processes of glucocorticoid anti­
inflammatory action are summarised in Figure 1.12.
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Figure 1.12: Schemes showing the two processes by which corticosteroids 
facilitate their anti-inflammatory action. Trans-activation is the production o f anti­
inflammatory mediators and trans-repression is the inhibition o f the production 
o f pro-inflammatory mediators (Barnes 2010).
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1.2.3: Anticholinergic bronchodilators
Anticholinergic bronchodilators are commonly used in the management of 
COPD but have also been used in the management of asthma either alone or in 
combination with other bronchodilator agents. Anticholinergic bronchodilators 
are the most effective class of bronchodilator in patients with COPD, this is 
because the airway cholinergic vagal tone is the only reversible component of 
the disease (Barnes 2004d).
1.2.3.1: Structures of anticholinergic bronchodilators
Modern anticholinergic bronchodilators are synthetic derivatives of atropine 
isolated from the berries of the deadly nightshade plant, Atropa Belladonna 
(Clark et a/., 1994). Anticholinergic bronchodilators such as ipratropium (Figure 
1.13A), which is a quaternary methyl isopropyl derivative of atropine contains a 
positively charged quaternary nitrogen. This makes the compound poorly 
absorbable by the respiratory mucosal surface and prevents systemic 
absorption and therefore minimises the risks of any possible side effects (Page 
and Barnes 2004).
Figure 1.13: Structure of A) the short-acting anticholinergic bronchodilator 
ipratropium and B) the long-acting anticholinergic bronchodilator tiotropium.
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1.2.3.2: Anticholinergic bronchodilator target
The target for anticholinergic bronchodilators are muscarinic receptors. There 
are three subtypes of muscarinic receptors located in the human airway 
designated M-i, M2 and M3 receptors as shown in Figure 1.14. These receptors 
have specific functions in the parasympathetic nervous system and control the 
day-to-day function of the lungs and other organs. The Mi receptors are located 
in the parasympathetic ganglia, their function is the cholinergic 
neurotransmission through the parasympathetic ganglia. The M2 receptors 
(autoreceptors) are located on the postganglionic cholinergic nerves and 
provide negative feedback to inhibit the release of acetylcholine. Finally, M3 
receptors are located on the bronchial smooth muscle and in the mucus glands, 
broncoconstriction and mucus secretion is mediated through these receptors 
(Page and Barnes 2004, Hansel and Barnes 2004).
Preganglionic
nerve
Nicotin ic  
receptors (+)P arasym pathetic
gangiion ACh
M i receptors  (+)
Postganglionic
nerve
^  M 2 receptors  (-)
AC h
A irw ay sm ooth m ^  ^  M 3 recep to rs  (+)muscle ,
Figure 1.14: Scheme showing the location o f the three muscarinic receptors. 
The M i receptors are located in the parasympathetic ganglion, the M2 receptors 
are located at the cholinergic nerve terminals and the M3 receptors are located 
on the airway smooth muscle and mucus glands (Barnes 2004d).
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1.2.3.3: Mechanism of action
Inhaled anticholinergic agents are muscarinic receptor anatagonists that block 
the parasympathetic neurotransmitter acetylcholine which causes 
bronchoconstriction and mucus secretion. Acetylcholine is released by 
cholinergic nerve endings that innervate the lungs, which binds to muscarinic 
receptors in the smooth muscle and airway submucosal glands this causes 
bronchoconstriction and mucus secretion (Barnes 2004d). The mechanism of 
action of anticholinergic agents is shown in Figure 1.15, the anticholinergic 
agent binds to the muscarinic receptor and prevents acetylcholine from binding 
thus preventing bronchoconstriction and mucus secretion.
Vagus nerve ending
Anticholinergic agent — — — — ^  ....................  Acetylcholine
  Muscarinic receptor
Smooth muscle 
ormucus gland
Bronchoconstriction 
Mucus secretion
Figure 1.15: Diagram showing the mechanism o f action o f anticholinergic 
bronchodilators (Image adapted from www.pharmacologycorner, com).
Tiotropium selectively blocks the Mi and M3 receptors and dissociates slowly, 
giving long-acting bronchodilation (-24 hours). This has the advantage of 
providing a once daily treatment with tiotropium. In contrast, ipratropium non- 
selectively blocks all three types of muscarinic receptors and dissociates from 
the receptors more quickly resulting in short-action bronchodilation (~4-6 
hours).
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1.3. Introduction to Mass Spectrometry
A mass spectrometer consists of an ion source for the creation of gas phase 
ions, a mass analyser for the separation of these ions according to their mass to 
charge ratio and a detector which “counts” the number of ions for each mass to 
charge ratio emerging from the mass analyser. The mass analyser and detector 
components are operated under high vacuum conditions; this is illustrated 
below in Figure 1.16.
Sample
Introduction
Ionisation
Source
Mass
Analyser Detector
Data
Analysis
Figure 1.16: Simplified schematic o f a mass spectrometer showing the three 
main components in blue.
In some instances the mass spectrometer may have a sample introduction 
component at the front of the instrument for example automated sample 
introduction robotics followed by chromatographic separation. All modern mass 
spectrometers utilise computers for instrument control and data collection.
1.3.1. Ionisation Sources
1.3.1.1. Matrix-Assisted Laser Desorption/Ionisation
Matrix-assisted laser desorption/ionisation (MALDI) was initially developed by 
Karas, Hillenkamp and co-workers in the late 1980’s (Karas et al., 1985). Co­
incidentally around the same time a closely related technique was developed by 
Tanaka et al., which involved mixing the analyte of interest with a suspension of 
ultrafine cobalt powder in glycerol (Tanaka et al., 1988). Essentially MALDI is an 
extension of the laser desorption ionisation (LDI) technique that was introduced 
in the late 1960’s. The advantages of LDI are it requires no special sample
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preparation in comparison to MALDI, however due to the increased energy 
extensive fragmentation and a loss of chemical information is observed. Whilst 
MALDI is now the commonly used method LDI is still useful for the analysis of 
certain compounds such as fullerene and crude oil.
In profiling experiments the analyte is mixed with an excess solution of the 
matrix, which is a low molecular weight organic compound that absorbs the 
energy at the wavelength of the laser. The result is the formation of analyte- 
doped matrix crystals, the laser ablates the crystals which causes the excitation 
and heating of the matrix which causes desorption and ionisation in the gas 
phase.
The principle of the MALDI technique is illustrated below in Figure 1.17.
laser
analyte/matrix spot bearn
analyte
ions
matrix
ions
cation
^ To mass 
spectrometer
sample plate extraction focussing 
gnd lens
Figure 1.17: Schematic representation o f the matrix-assisted laser
desorption/ionisation process, showing the analyte (green dots) embedded  
within the matrix (blue dots) the laser is then fired at this mixture causing 
desorption and subsequent ionization in the gas phase o f both matrix and  
analyte molecules that are sampled by the mass spectrometer 
(www. chm. bris.ac. uk).
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MALDI was later developed into an imaging technique by (Spengler et al., 
1994). The initial work demonstrated the imaging of a dried mixture of the matrix 
2,5-dihydroxybenzoic acid and the peptide substance P using the LAMMA 2000 
scanning laser ion microprobe system the authors had developed. This concept 
was later extended for the analysis of tissue sections (Caprioli et al., 1997). In 
imaging experiments the matrix is uniformly applied Onto the surface of the 
sample, this causes the analytes within the tissue to migrate to the surface upon 
which the matrix and the analyte form co-crystals.
Whilst the use of MALDI is widely accepted in the scientific community, the 
underlying mechanism of the desorption and ionisation processes involved are 
not fully understood and are still under investigation. Current understanding of 
both the desorption and ionisation have been extensively reviewed (Dreisewerd 
2003, Knochenmuss 2006).
1.3.1.1.1 Ion formation in MALDI
The ionisation process in MALDI is generally thought to occur as a two step 
process; the primary ionisation occurs during or soon after the laser pulse 
followed by secondary reactions in the expanding plume of desorbed material 
(Knochenmuss 2006).
The formation of primary ions remains the most controversial aspect in MALDI 
and many theories have been proposed over the years.
The multiphoton ionisation is bar far the simplest explanation of ion formation 
resulting from laser excitation of the MALDI matrix, leading to the formation of a 
matrix radical cation (Zenobi and Knochenmuss 1998). This is represented by 
the following equation:
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The cluster model originally called the “lucky survivor” model was introduced by 
(Karas et al., 2000). It is thought that the analyte retains a charge upon 
incorporation into the solid matrix preparation, upon irradiation with the laser 
clusters are desorbed and in the gas phase neutral matrix and solvent 
molecules are lost. Extensive neutralisation is then thought to occur in the 
plume therefore the ions detected are the “lucky survivors” and explains the 
presence of singly charged ions (the only species to be observed in MALDI). 
Following formation the initial primary ions then interact with neutral molecules 
in the expanding plume of desorbed material, these reactions result in the 
formation of secondary ions that are finally detected and observed in the mass 
spectrum. There are three types of secondary reactions that can occur these 
are known as proton, electron and cation transfer reactions.
The proton transfer reaction is the most important secondary reaction in MALDI. 
The proton transfer occurs between the protonated matrix and neutral analyte 
and is driven by the proton affinities of the analyte and matrix. The reaction is 
shown below:
MH+ + A —> M + AH+
The cation transfer reaction is the more favourable mechanism for analytes with 
low proton affinity less than that of the matrix (Knochenmuss and Zenobi 2003). 
This process is observed with the analysis of synthetic polymers and 
carbohydrates. The additions of sodium or potassium salts to the matrix can be 
used to promote the cationisation of certain analytes. This process is illustrated 
in the equation below:
MNa+ + A —► M + ANa+
The role of the matrix in the cationisation process has been investigated by 
(Zhang etal., in 2004).
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The electron transfer reaction is not very common but can occur when the 
ionisation potential of the matrix is greater than that of the analyte leads to the 
formation of analyte radical cations. The reaction is shown below:
M+’ + A -> M + A+*
1.3.1.1.2. MALDI matrices
Several matrices have been developed for MALDI and MALDI imaging. The 
selection of the matrix is an important parameter to consider and the choice is 
based on the analyte of interest.
The most commonly used matrices are either benzoic or cinnamic acid 
derivatives. Sinapinic acid (SA) is routinely used for the analysis of high 
molecular weight compounds such as proteins whilst a-cyano-4- 
hydroxycinnamic acid (CHCA) is more commonly used for low molecular weight 
compounds such as drugs, lipids and peptides (Bevis and Chait 1989, Bevis et 
al., 1992, Schwatrz et al., 2003). 2,5-dihydroxybenzoic acid (DHB) is commonly 
used in the analysis of drugs and lipids (Strupat et al., 1991).
9-Aminoacridine (9-AA) was first introduced by Vermillion-Salsbury and 
Hercules in 2002 as a matrix for the analysis of acidic compounds in negative 
ion mode by MALDI-MS; 9-AA is a strong base and readily accepts protons in 
comparison to established matrices such as CHCA which is an acid that readily 
donates protons. The ionisation mechanism of 9-AA in negative ion mode is 
thought to occur by the abstraction of protons in an acid/base reaction leading 
to the formation of de-protonated species ([M-H']).
It has been demonstrated by (Guo and Ze 2007) that a mixture of the acidic 
matrix CHCA and the basic matrix 9-AA, act as a binary matrix to reduce the
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background noise associated with matrix adducts. This matrix preparation also 
enables switching between polarities without further sample preparation.
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A summary of the most common MALDI matrices is shown below in Table 1.1, 
this is not an exhaustive list and new matrix candidates and matrix preparations 
are reported on a regular basis.
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Table 1.1: Some o f the commonly used MALDI matrices including their 
structure and the analyte classes they have been applied to.
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1.4.2. Secondary Ion Mass Spectrometry
Secondary ion mass spectrometry (SIMS) is a surface analysis technique 
commonly used in materials research especially in the semiconductor industry 
(McPhail 2006). SIMS imaging is a complementary technique to MALDI-MSI 
and is capable of producing high spatial resolution images (<1 pm).
In SIMS, a high energy primary ion beam is directed onto a sample surface 
which penetrates the surface region and induces a collision cascade. This 
results in the release of secondary ions in the form of neutral and charged 
secondary species.
There are two modes of operation called static SIMS which is used for surface 
analysis and dynamic SIMS which is used to analyse the samples depth profile. 
Static SIMS uses a low primary ion dose, which minimises the interactions of 
the primary ions to the top monolayers of the sample resulting in minimal 
surface damage. Dynamic SIMS on the other hand utilises a high primary ion 
dose, which interacts with deeper layers of the sample, this cause the sputtering 
of the sample surface and enables the production of a depth profile.
This generation of secondary ions is illustrated in Figure 1.18.
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Figure 1.18: Schematic representation o f the secondary ion mass spectrometry 
process, showing the primary ion beam (blue dots) which strikes the sample 
causing the production o f secondary ions (www.mse.engin. umich. edu).
Application of a thin metal coating such as gold for Metal assisted-SIMS (MetA- 
SIMS) or the application of MALDI matrices for matrix enhanced-SIMS (ME- 
SIMS) have been developed to enhance the production of intact secondary ions 
and reduce fragmentation (McDonnell et al., 2005, Altelaar et al., 2007).
One of the main limitations of the SIMS technique is the ion source is usually 
coupled to time-of-flight or magnetic sector mass analysers and as a result the 
technique has low mass resolving power and no MS/MS capabilities (Prideaux 
and Stoeckli 2012).
In order to overcome these limitations several groups have investigated the 
connection of primary ion sources to commercially available instruments, an 
example by the Winograd group described the connection of a C6o primary ion 
gun to an Applied Biosystems QSTAR instrument. This instrument 
demonstrated improved mass accuracy and resolving power (14,000), MS/MS
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capabilities and capable of achieving a spatial resolution of around 30pm 
(Carado et al., 2008).
Another example recently reported by Smith et al., described the connection of 
a C6o primary ion gun to a fourier transform ion cyclotron resonance mass 
spectrometer. This instrument demonstrated both high mass resolution 
(-100,000) and accuracy (1 ppm), MS/MS capabilities and capable of achieving 
a spatial resolution of around 40pm (Smith et al., 2012).
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1.4.3. Electrosprav Ionisation
Electrospray ionisation (ESI) was first introduced by Dole and co-workers in 
1968 and later coupled to a quadrupole mass analyser in 1984 by Yamashita 
and Fenn.
ESI is accomplished by passing a solution of analyte through a needle held at a 
high electrical potential into a chamber at atmospheric pressure. The high 
electric potential in the range of 3-6 kV is applied between the capillary and 
cone and causes an accumulation of positively charged ions at the tip of the 
capillary, to form what is known as a Taylor cone (Hoffmann and Stroobant 
2007). When the imposed electric field is high enough the cone elongates, 
which then breaks and forms a spray of charged droplets (Gaskell 1997). A 
schematic of an ESI source is shown below in Figure 1.19.
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Figure 1.19: Schematic representation o f an electrospray ionisation source. 
Showing the formation o f a Taylor cone at the tip o f the capillary and the 
production o f a spray o f charged droplets due to an applied electric potential 
(Image adapted from Kebarle 2000).
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The solvent component of the droplet begins to evaporate with the aid of a 
stream of nitrogen gas and the diameter of the droplets is reduced, eventually 
the charge density becomes greater than the surface tension of the droplets. 
The point at which this occurs is known as the Rayleigh limit and at the point a 
process called Coulombic explosion occurs resulting in desorption of the ions 
into the gas phase. This process is known as the ion evaporation method and is 
more favourable for small molecular weight compounds (Baldwin 2005, El- 
Aneed et al., 2009, Gaskell 1997). An alternative process known as the charge 
residue method can also occur, this results in the complete desolvation of 
droplets to form a single ion. This process is more favourable for large 
molecular weight compounds (Baldwin 2005, El-Aneed et al., 2009). Both 
methods of ion formation are illustrated below in Figure 1.20.
Figure 1.20: Diagram showing the two methods of ion formation in ESI. After 
the creation of a spray of charged droplets Coulombic explosion followed by 
desorption of ions from the surface can occur according to the ion evaporation 
method or the solvent can completely evaporate according to the charge 
residue method (El-Aneed et al., 2009).
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1.4.4. Desorption Electrosprav Ionisation
Desorption electrospray ionisation (DESI) is an ambient ionisation technique for 
mass spectrometry introduced by (Takats et al., 2004).
The technique works by directing a spray of charged droplets produced from a 
pneumatically assisted electrospray onto a sample surface, the impact of these 
charged droplets produces a thin layer of solvent on the sample surface that 
extracts the analytes. It is upon the impact of subsequent charged droplets that 
causes the production of secondary microdroplets containing the dissolved 
analytes hence the term “droplet pickup” (Costa and Cooks 2008). A schematic 
of a DESI source is illustrated below in Figure 1.21.
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Figure 1.21: Schematic representation o f the desorption electrospray ionisation 
source, showing the spray o f charged droplets (red dots) that is directed  
towards the sample the impact o f the charged particles results in the production  
o f gaseous ions o f analytes originally on the sample surface that are sampled 
by the mass spectrometer (Takats et al., 2004).
DESI-MS was first demonstrated for the imaging of biological tissue sections by 
(Wiseman et al., 2006). The first application of DESI-MS imaging to the
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monitoring of the distribution of pharmaceutical compounds in tissue sections 
was later presented by (Wiseman et al., 2008). In this work the distribution of 
the antipsychotic drug clozapine was monitored throughout rat brain, lung, 
kidney and testis tissue sections, the signal intensity of clozapine obtained from 
the images showed good correlation with quantitative data obtained from LC- 
MS/MS.
Kertesz et al., demonstrated the use of DESI-MS/MS imaging to monitor the 
distribution of the drug propranolol throughout whole body tissue sections of a 
mouse, the resulting images were comparable with WBA distribution data.
The spatial resolution that can be achieved by DESI is 150-250 pm. However 
Kertesz and Van Berkel demonstrated in 2008 that with optimised parameters 
such as the distance between the spray tip and sample and solvent flow rate, 
an imaging spatial resolution of approximately 40 pm can be achieved.
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1.4.5. Laser Ablation Electrospray Ionisation
Laser ablation electrospray ionisation (LAESI) is a novel ion source originally 
developed by Akos Vertes and Peter Nemes in 2007 for producing ionised 
molecules for mass spectrometric analysis in normal atmospheric conditions 
from samples with a high water content e.g. plant tissues (Nemes and Vertes
2007).
The technique works by desorption of small portions of the sample into the gas 
phase and subsquent ionisation by an electrospray ion source. A mid infra-red 
laser (wavelength 2940 nm) is fired at the sample in order to excite the O-H 
bonds of the water molecules within the sample. This causes phase explosion 
leading to microscale ablation and ejection of neutral particulates. The particles 
are then intercepted by highly charged droplets from the ESI source, which 
captures a small amount of the emitted particles (Nemes etal., 2009). From this 
point the gaseous ions are produced in a similar process to ESI and as a result 
the mass spectra exhibits multiply charged analyte peaks. Figure 1.22 shows 
the schematics of the LAESI ion source.
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Figure 1.22: Schematic representation o f the laser ablation electrospray 
ionisation source, showing the production o f ablated material (red dots) which 
are intercepted by the electrospray plume (black dots) and post-ionised to form  
ions (green dots) that are sampled by the mass spectrometer (Image adapted  
from Sh rest ha et a I., 2010).
Mass Spectrometric Imaging using LAESI has been used to monitor the 
distribution of endogenous proteins within biological tissue sections making the 
technique comparable to MALDI-MSI. Recently a commercial model based on 
the original research conducted by Vertes and Nemes has been produced by 
Protea Biosciences Inc., called the LAESI DP-1000 
(https://proteabio.com/LAESI) and can currently be fitted onto Thermo and 
Waters instruments.
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1.5: Mass Analysers 
1.5.1: Time-of-Flight 
1.5.1.1: Linear time-of-flight mode
The concept of the time-of-flight (TOF) mass analyser was proposed by 
Stephens in 1946. The design of a linear TOF instrument was proposed by 
Wiley and McLaren in 1955 and later became the first commercial instrument. 
Ions formed in the MALDI source are accelerated towards the flight tube by a 
potential applied between the sample plate and the extraction grid, this imparts 
a constant kinetic energy on the ions as they enter the field-free flight tube. The 
ions will then separate according to their velocities, which will depend on their 
respective mass before reaching the detector (Hoffmann and Stroobant 2007). 
Briefly, lighter ions have shorter flight times than those of heavier ions 
(Castleberry et al., 2008), this is illustrated below in Figure 1.23.
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Ion Source Region
extraction lenses
sample plate
F
■ ■
t
I I
detector
flight tube
m a s s 0  > m ass0
Figure 1.23: Schematic o f a time-of-flight mass analyser operated in linear 
mode, ions are produced and accelerated by an applied potential (accelerating 
voltage) into the field-free flight tube where the ions separated based on their 
velocity. Lighter ions (blue dots) travel faster than larger ions (red dots) and 
therefore reach the detector first (Image adapted from Castleberry et al., 2008).
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1.5.1.2: Reflectron time-of-flight mode
Improvements in the mass resolution and reductions to the kinetic energy 
spread amongst ions with the same m/z value, can be achieved by using an ion 
mirror, or reflectron.
The reflectron was introduced by (Mamyrin et al., 1973) and is composed of a 
series of ring electrodes that create an electric field by way of a linear voltage 
gradient. The principle behind reflectron mode is that ions with more kinetic 
energy will travel further into the reflectron than ions with lower kinetic energy. 
However because of this the ions will reach the detector at the same time 
(Hoffmann and Stroobant 2007). This is shown below in Figure 1.24.
Reflectron Ttme-of-Flight
linear detector
mass ~ m a s s f 
energy 0  < en erg y^sample plate
Figure 1.24: Schematic o f a time-of-flight mass analyser operated in refectron 
mode, ions (blue dots) with more kinetic energy and velocity will penetrate the 
reflectron more deeply than those with lower kinetic energy (red dots) resulting  
in the ions reaching the second detector at the same time (Image adapted from  
Castleberry et al., 2008).
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1.5.2. Quadrupole
The quadrupole component of the mass spectrometer acts as a mass filter, 
which consists of four parallel rods. These rods are connected in pairs, to which 
a radio frequency (RF) voltage along with a direct current (DC) voltage is 
applied.
The theory behind the quadrupole is that the ions are separated based on the 
stability of their trajectories in the oscillating electric fields that are applied to the 
rods (Hoffmann and Stroobant 2007). Basically a quadrupole works by allowing 
ions of a certain mass-to-charge ratio (m/z) to travel between the metal rods 
and reach the detector for a given ratio of voltages, whilst other ions will collide 
with the metal rods and be neutralised, as illustrated in the schematic below in 
Figure 1.25.
cuadrupole rocs
exit slit 
(to detector)
resonant ior 
(detected)
non-resonance ion 
(not detected)
Figure 1.25: Schematic representation o f a quadrupole mass analyser, the red  
ion is o f the correct mass-to-charge and is able to traverse the quadrupole 
whilst the blue is o f a different mass-to-charge and is neutralised on the metal 
rods (www. chm. bris. ac. uk).
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1.6. Hybrid Mass Spectrometers
1.6.1: Quadrupole Time-of-Fliqht Mass Analyser
The majority of the MALDI-Mass Spectrometry data presented within this report 
was acquired using an Applied Biosystems/MDS Sciex Q-Star Pulsar-/ hybrid 
quadrupole time-of-flight mass spectrometer fitted with an orthogonal MALDI ion 
source (Applied Biosystems, Foster City, California, USA). This instrument is an 
example of a “hybrid” mass spectrometer that combines two mass analysers (a 
quadrupole and time-of-flight) for improved sensitivity and mass resolution, this 
setup is illustrated below in Figure 1.26.
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Figure 1.26: Schematic of a Hybrid Quadrupoie Time-of-Flight with an 
orthogonal MALDI ion source (Baldwin et al., 2001).
The Q-Star Pulsar-/ instrument consists of three quadrupoles (Qo, Qi and Q2) 
followed by a reflectron time-of-flight mass analyser with orthogonal ion 
injection. Quadrupole (Qo) is operated in RF-only mode and is used to “cool” the
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kinetic energy of the ions and focus them into quadrupole (Qi) (Chernushevich 
et al., 2001).
For a conventional TOF-MS measurement, all three quadrupoles are both 
operated in RF-only mode and act as ion guides allowing the passage of ions 
with a wide range of m/z values, the ions are then focused into the orthogonal 
time-of-flight mass spectrometer for detection (Hoffmann and Stroobant 2007). 
For TOF-MS/MS (product ion scan) measurements (the parameters are 
changed) the quadrupole (Qi) is used as a mass filter to select a particular ion 
of interest, by adjusting the offset voltages of the quadrupoles. The ions of 
interest are accelerated into the second quadrupole which acts as a quadrupole 
collison cell (Q2) where they collide with a neutral gas (argon or nitrogen) and 
undergo collision induced dissociation. The product ions are then focused into 
the orthogonal time-of-flight mass spectrometer and detected (Chernushevich et 
a/., 2001).
In order to achieve orthogonal ion injection into the time-of-flight mass analyser 
an ion modulator is used, the schematic of this device is shown below in Figure 
1.27. The basic principle of this device is that ions are accelerated into the 
device from the last quadrupole (Q2) and then using a pulsed electric field the 
ions are pushed orthogonally to their original trajectory into the acceleration 
column. From here the ions enter the field-free drift space where the ions 
undergo time-of-flight separation, an ion mirror corrects the energy and spread 
of ions before they reach the detector (Hoffmann and Stroobant 2007, 
Chernushevich e ta l., 2001).
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Figure 1.27: Schematic of the ion modulator of the Time-of-Flight mass 
analyser from a hybrid instrument (Chernushevich et a l, 2001).
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1.6.2. Tandem Time-of-Fliqht (TOF/TOF)
An example of a tandem time-of-flight (TOF/TOF) instrument and the one used 
to generate some of the data in this thesis is the Ultraflex series of mass 
spectrometers from Bruker Daltonics (Bruker, Bremen, Germany). The 
technology at the centre of this instrument is the LIFT cell that employs a 
potential lift to accelerate fragment ions.
This instrument is comprised of a short linear TOF analyser, a timed ion 
selector (TIS) to deliver ions into a collision cell, and a linear/reflector TOF 
analyser (Medzihradszky et al., 2000, Suckau etal., 2003).
The schematic of the MALDI-LIFT-TOF/TOF mass spectrometer is shown 
below in Figure 1.28.
Post Lift 
Metastable Gridless ReflectorSuppressor
(PLMS)Timed Ion Selector Source 2Sample Target
T0F1 T0F2
Gridless DE 
MALDI Source Collision
Cell DetectorDetector Analyzer
Ion Source
Figure 1.28: Schematic of the MALDI-LIFT-TOF/TOF mass spectrometer 
showing the MALDI ion source, the first TOF with timed ion selector, the LIFT 
and the second TOF with gridless reflector (Suckau et al., 2003).
For MS/MS experiments the instrument works by operating the first TOF at low 
acceleration voltage (around 8 keV), the precursor ion of interest is selected 
using the time ion selector which delivers the precursor ion to a collision cell for 
fragmentation by collision induced dissociation (CID). The fragment ions are
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then accelerated to around 20 keV using the LIFT cell into the second TOF 
which is a high resolving reflector TOF (Suckau et al., 2003, Cotter et al., 2007).
1.6.3. Quadrupole-lon Mobility Separation-Time-of-Fliqht Mass Spectrometer 
Ion mobility separation adds another dimension to mass spectrometric analysis, 
it separates ions based on their size/charge ratio in a drift tube containing a 
buffer gas under the influence of an electric field (Kanu et al., 2008). Gas phase 
separation occurs due to the ions having differing collisional cross-sections and 
can separate isobaric species. The schematic of the MALDI HDMS SYNAPT 
G2 system is shown below in Figure 1.29.
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Figure 1.29: Schematic o f the Waters MALDI HDMS SYNAPT G2 system, this 
instrument has a quadrupole orthogonal acceleration time-of-flight geometry 
and is equipped with an ion mobility separation device located between the 
quadrupole and the time-of-flight analysers. The “triwave” ion mobility 
separation device consists o f three regions the trap, ion mobility separation and  
transfer regions (Waters Corporation, Manchester, UK).
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The “Triwave” is the key technology at the centre of the SYNAPT HDMS 
system, it is comprised of three travelling wave enabled stacked ring ion guides 
(SRIGs). The trap cell is used to accumulate ions, which are released in 
packets into the ion mobility cell for mobility separation. Following this the 
mobility separated ions are transferred to the orthogonal acceleration time-of- 
flight analyser (Pringle et al., 2007).
This technique has been employed in mass spectrometry imaging for the 
separation of ions from endogenous or matrix related isobaric species. One 
such application reported by (McLean et al., 2007) utilised this technique for the 
separation of two spatially structured isobaric species in this case a peptide and 
a lipid resolved in a MALDI-IMS-MS imaging experiment (McLean et al., 2007). 
Another example reported by (Trim et al., 2009) is the imaging of the distribution 
of the anticancer drug Vinblastine in whole body tissue sections of a rat. The 
MS and MS/MS imaging results obtained demonstrated the separation of 
Vinblastine from interfering isobaric species (e.g. lipids), resulting in a higher 
confidence in the data (Trim et al., 2009).
New instruments that incorporate ion mobility separation technology have been 
developed. AB Sciex has introduced the SelexlON™ an interchangeable ion 
mobility separation cell that can be fitted onto the AB Sciex 5500 and 6500 triple 
quadrupole or quadrupole ion trap mass spectrometers (www.absciex.com). 
Agilent Technologies have recently introduced the Agilent 6560 ion mobility Q- 
TOF LC-MS instrument that incorporates a drift tube based ion mobility cell 
(www.chem.aqilent.com).
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1.7. Mass Spectrometry Imaging
1.7.1. Microprobe Imaging Mode
Microprobe mode is the most common approach to mass spectrometry imaging. 
It is accomplished by performing a programmable pattern of laser shots over the 
coated tissue section in an array to generate a full mass spectrum at each x, y 
co-ordinate (Khatib-Shahidi et al., 2006). Once the entire tissue has been 
analysed imaging software is used to produce signal density maps of a selected 
molecular ion by plotting the x, y co-ordinates against the relative abundance 
and intensity of the selected m/z value (Reyzer et al., 2007). The limitations of 
microprobe mode are that the achievable imaging resolution depends on the 
laser spot size and the acquisition time increases dramatically with increased 
resolution.
1.7.2. Microscope imaging mode
Microscope imaging mode was pioneered by Ron Heeren and co-workers at 
FOM Institute AMOLF (Amsterdam, The Netherlands). In microscope mode the 
sample is irradiated with a large diameter laser beam (-200 pm). The ions 
generated retain their spatial distribution until they reach a position sensitive 
detector (Altelaar et al., 2007, Klerk etal., 2009).
With this mode of acquisition the spatial resolution is determined by the quality 
of the ion optics and the resolving power of the detector, rather than the laser 
spot size (Luxembourg et al., 2004).
Using this configuration a spatial resolution of 4 pm has been achieved 
(Luxembourg et al., 2004).
The advantages of the microscope mode are: the high spatial resolution is 
independent of the laser spot size and the amount of sampling points is reduced
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thus reducing the acquisition time (Luxembourg et al., 2004, Klerk et al., 2009). 
However the ion optics and detection system required are more expensive and 
are only compatible with time-of-flight or magnetic sector analysers (Pol et al., 
2010).
A comparison between microprobe and microscope modes is illustrated in 
Figure 1.30.
A) MICROPROBE MODE
Image reconstructed from 
position-correlated spectra
B) MICROSCOPE MODE
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Position sensitive 
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ions of different mass 
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Magnified 
molecular images
Figure 1.30: Schematics of the two approaches to mass spectrometry imaging. 
Microprobe mode A) collects mass spectra from an array of designated 
sampling positions to reconstruct an image after completion of the experiment. 
In microscope mode B) magnified images of ion distributions are directly 
acquired using a position sensitive detector (Luxemborg et al., 2004).
1.7.3. Raster Imaging Mode
The majority of mass spectrometry images presented within this thesis were 
acquired in “raster” imaging mode developed by AB Sciex, this method of data 
acquisition is achieved by continuously firing the laser in rows across a sample 
as shown in Figure 1.31. In this acquisition method the generated data is placed 
into “bins” at selected intervals during the raster, these are based upon the 
selected spatial resolution and sampling speed (Trim et al., 2010).
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Figure 1.31: Diagram showing the conventional spot-to-spot (left) and the 
raster (right) acquisition modes (Simmons 2008).
For the conventional spot-to-spot method the main disadvantage is the 
acquisition time, which is increased with tissue size and image resolution, also 
the sensitivity is reduced by this method of acquisition because there are 
spaces between the laser shots that is not sampled. In contrast, the raster 
acquisition mode overcomes these disadvantages by decreasing the acquisition 
time without compromising the sensitivity and image resolution (Simmons
2008). Making this type of acquisition mode ideal for high throughput screening 
of multiple samples.
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1.8. Matrix application/ deposition for MALDI Imaging
Matrix deposition is the most important step of the sample preparation 
procedure in a MALDI imaging experiment. This requires the matrix solution to 
be applied over the entire tissue sample prior to analysis. The matrix solution 
consists of the chosen matrix in a mixture of organic solvent (e.g. methanol or 
acetonitrile) and water with the addition of a strong acid (such as trifluoroacetic 
acid). The purpose of the organic solvent is to extract the analyte from the 
tissue section and evaporate, the analyte is then incorporated into the matrix 
crystals that form on the sample surface. The solvent to water ratio effects the 
formation and size of the matrix crystals, a higher solvent ratio leads to faster 
evaporation and produces smaller crystals. Several methods and instruments 
have been used for matrix application, which are discussed in the following 
section.
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1.8.1. Airbrush
The use of a pneumatically assisted airbrush for matrix deposition is the 
simplest and cheapest method available. However, the use of this method 
requires skilful operation. For reproducible matrix application there are many 
parameters that need to be considered such as the distance and angle the 
airbrush is held from the sample, the amount of matrix applied per cycle, the 
number of cycles applied, the temperature and the humidity.
Probably the most important aspect to consider is the amount of matrix applied 
onto the sample, it is crucial that the sample is sufficiently wet to allow analyte 
extraction but not to over wet the sample, which can lead to analyte migration 
(Schwartz et a/., 2003).
An example of the kind of airbrush used for manual matrix deposition is shown 
below in Figure 1.32.
nmr
Figure 1.32: Image of the Iwata Eclipse HP-CS airbrush used for manual matrix 
deposition (www.iwata-medea.com).
The advantages of using the airbrush application method are that it is fast,
simple, cheap and with skilful operation can produce a homogenous matrix
coverage. However the disadvantages are that there are limited environmental
controls, the quality of the preparation differs from person to person and the
droplet size is inconsistent (Kaletas et al., 2009). Whilst this method may be
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employed for matrix deposition, most laboratories have opted to use an 
automated matrix deposition device as they provide a more reproducible and 
homogenous matrix coating.
1.8.2. Suncollect
The Suncollect MALDI spotter (Sunchrom, Friedrichsdorf, Germany) is used to 
precisely spot HPLC fractions onto MALDI target plates or can be operated as 
an automated pneumatically assisted matrix sprayer.
This device has also been used to deposit enzymes such trypsin onto tissue 
samples for the purpose of in-situ protein digestion (Djidja et al., 2010, Cole et 
ai, 2011). The Sunchrom Suncollect automated matrix sprayer is shown below 
in Figure 1.33.
Figure 1.33: Image of the Sunchrom Suncollect automated matrix sprayer 
(Image from www. sunchrom. de).
The advantages of the Suncollect automated matrix sprayer are that it produces 
an homogeneous matrix coating, it is automated and thus suitable for large 
areas and environmental factors (such as humidity and temperature) can be
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controlled. However the disadvantages are the device is prone to clogging and 
the droplet size is not constant (Kaletas et a i, 2009).
1.8.3. ImaqePrep
The Bruker ImagePrep matrix deposition device (Bruker Daltonics, Bremen, 
Germany) creates a matrix aerosol by vibrational vaporisation, which is gently 
deposited onto the sample (Schuerenberg et a i, 2007). The device has an 
optical sensor that monitors the scattered light from the crystalline matrix layer 
on the sample enabling control of all the relevant parameters (such as the 
matrix thickness, wetness and drying rate) in real time. The Imageprep matrix 
deposition device is shown below in Figure 1.34.
Figure 1.34: Image of the Bruker ImagePrep™ matrix deposition device (Image 
from www.bdai.com).
The advantages of the imageprep matrix deposition device are that the 
experimental conditions can be optimised and controlled, the device is 
automated and produces homogeneous matrix coverage. However the 
disadvantages are the device is slow, the spray foil is prone to clogging and it is 
expensive (Kaletas et ai., 2009).
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1.8.4. Portrait
The Labcyte Portrait® 630 Reagent Multi-Spotter (Labcyte Inc. California, USA) 
uses ultra-sound based acoustic droplet ejection (ADE) to deposit the matrix 
onto the sample in an array consisting of droplets of approximately 170 pi. The 
Portrait 630 reagent multi-spotter is a commercial version based on the acoustic 
spotter prototype device developed by (Aerni et a i, 2006).
A piezoelectric transducer converts radio frequency power into ultrasonic 
energy, which is then transmitted through the reagent reservoir causing the fluid 
to form a droplet that travels upwards onto the inverted sample above. The fluid 
is kept on the sample by surface tension. The portrait 630 reagent multi-spotter 
is shown below in Figure 1.35.
Figure 1.35: Image of the Labcyte Portrait® 630 Reagent Multi-Spotter 
instrument (Image from www.labcvte.com).
The advantages of the portrait 630 reagent multi-spotter are that it produces 
uniform droplets with precise placement, it is automated and the absence of 
nozzles means it does not clog and has good reproducibility. However the
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disadvantages are the instrument is slow and expensive and applies the matrix 
as droplets and the distance between them defines the spatial resolution 
(Kaletas etal., 2009).
1.8.5. Sublimation
Sublimation was introduced as a matrix deposition method by (Hankin et a i, 
2007). In this study the sublimation method was used to apply the common 
MALDI matrix DHB onto mouse brain tissue sections, this enabled high spatial 
resolution images of phospholipids. The sublimation method was also used to 
deposit DHB onto a phospholipid standard, the results showed an improved 
signal intensity in comparison to the electrospray matrix deposition method.
The method employed by (Hankin et a i, 2007) involves attaching the sample to 
a condenser (maintained at 15°C) with double sided thermal conductive tape 
facing solid matrix powder. The matrix is then slowly heated to 120°C under low 
pressure (0.05 Torr) for 15-20 minutes, the matrix then sublimates and 
condenses on the sample surface. The equipment setup from matrix 
sublimation is shown in Figure 1.36.
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Figure 1.36: Image of sublimation equipment used to apply the matrix onto 
tissue samples. The image shows the tissue sample on a MALDI plate mounted 
to the underside of the condenser and the matrix powder in the bottom part of 
the apparatus (Hankin et ai, 2007).
Recently sublimation has been used to evaluate the use existing and novel
matrices for high spatial resolution imaging of lipids in mouse brain and whole
body fish tissue sections. In this study the matrix 1,5-diaminonapthalene (DAN)
gave the best results following sublimation (Thomas et al., 2012).
The main advantage of sublimation deposition in comparison to the other matrix
application techniques is it is a solvent free method and as a result eliminates
the possibility of analyte diffusion (Hankin et al., 2007, Murphy et al., 2011).
However there is limited analyte-matrix interaction and at present this method
has only applied to lipids (Kaletas et a i, 2009).
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The application of the sublimation matrix deposition method to proteins and 
peptides requires re-wetting of the surface to enable extraction and 
recrystallisation of analytes (Yang and Caprioli 2011).
1.8.6. ChIP chemical inkjet printer
The ChlP-1000 chemical inkjet printer (Shimadzu Corporation, Tokyo, Japan) is 
a piezoelectric-based chemical ink-jet printer. The instrument uses piezo 
printing heads and nozzles that do not touch the sample surface, to deposit 
approximately 100 pi of the matrix onto the sample that dries to form a 100-250 
pm diameter spot. The ChlP-1000 chemical inkjet printer is shown below in 
Figure 1.38.
Figure 1.37: Image of the Shimadzu ChlP-1000 chemical inkjet printer (Image 
from www. ssi. shimadzu. com).
The advantages of the ChlP-1000 chemical inkjet printer are that it produces 
uniform droplets with precise placement which minimises cross-contamination, 
it is automated and has good reproducibility. However the disadvantages are
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the instrument is slow, the nozzle tip is prone to clogging when concentrated 
matrix solutions are used and it is expensive (Kaletas et al., 2009).
The adaptation of a desktop inkjet printer into an automated matrix deposition 
device was reported by (Baluya et al., 2007). The desktop inkjet printer used 
had a six channel piezoelectric head that could deliver 3 pi droplets of matrix 
onto a tissue section. A comparison of this device with other matrix deposition 
methods such as electrospray and airbrush methods showed that better quality 
and reproducible images could be obtained.
1.8.7. HTX TM-Soraver
The HTX TM-Sprayer (HTX Technologies, Carrboro, NC, USA) is another 
example of an automated matrix sprayer. It uses a heated spray nozzle to 
produce an aerosol of small droplets (20 pm), the heated and pressurised 
matrix solution is able to penetrate further into the tissue sample to facilitate 
better analyte extraction and co-crystallisation whilst minimising delocalisation. 
The instrument also uses nitrogen to control the rate of solvent evaporation to 
prevent the creation of large matrix crystals. The HTX TM-Sprayer is shown 
below in Figure 1.39.
TM-Sprayer
Figure 1.38: Image of the HTX TM-Sprayer (Image from www.htximaaina. com).
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Other advantages of this instrument are it is capable of high flow rates (200 
pl/minute), it is fast (10-20 minutes per plate), produces a homogeneous and 
reproducible matrix coating and the stage is capable of holding up to 10 glass 
slides making it ideal for high throughput preparation.
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1.9. Scope of this thesis
The main aim of the work reported in this thesis was the development of 
MALDI-MSI methods for monitoring the distribution of respiratory compounds in 
rodent lungs following inhaled delivery. In addition, developments to MALDI-MSI 
methodology and sample preparation strategies were also assessed with the 
aim of obtaining further information and enhancements to the field of MALDI- 
MSI.
Chapter 2 presents the development and application of a method utilising 
hydrazine based reagents for the derivatisation of a range of glucocorticoids, in 
an attempt to improve their mass spectral ionisation efficiency and thus 
detection both in-solution and on-tissue.
Chapter 3 describes the process of determining the feasibility of analysing a 
range of respiratory compounds by MALDI-MSI. The distribution of a selected 
respiratory compound was monitored throughout the lungs following inhaled 
delivery by MALDI-MSI. A comparison of the data obtained from the analysis of 
samples on different instruments is also presented.
Chapter 4 evaluates the current methods for generating quantitative information 
from mass spectrometry images, the advantages and disadvantages of each 
method is discussed. Also presented is a novel method for the preparation of 
standards for the quantitation of drugs in tissue sections by MALDI-MSI.
Chapter 5 introduces methodology to determine the three-dimensional 
distribution of endogenous species throughout the lungs by MALDI-MSI. The 
use of freely available software to produce a 3D reconstruction of a series of 
MALDI-MS images obtained through the sample is also presented.
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Chapter 6 summarises the work performed to generate this thesis and makes 
some conclusions along with recommendations for further studies.
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Chapter 2
Use of hydrazine based reagents for improved sensitivity and detection of 
glucocorticoids by MALDI-MSI
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2.1. Introduction
2.1.1. Purpose of derivatisation
One of the main aims of this research is to determine the distribution of 
corticosteroids in dosed rat lung tissue sections by MALDI-MSI. Corticosteroids 
contain multiple carbonyl functionalities which are not easily protonated/ de- 
protonated under mass spectrometry conditions, due to their low ionisation 
efficiencies. Derivatisation has been proposed as a solution to this problem by 
introduction of groups with fixed charges or with high proton affinity.
The most common derivatisation reactions of carbonyl compounds reported for 
analysis by “soft” ionisation mass spectrometry methods are based on the 
formation of oximes and hydrazones (Zaikin and Halket 2006). Other published 
methods involve the formation of Schiffs bases, semicarbazones and 
thiosemicarbazones (Vaiken and Halket 2009).
Another benefit of derivatisation in “soft” ionisation mass spectrometry 
techniques such as MALDI-MS is that it can help prevent matrix-related ion 
suppression and isobaric overlay between matrix and analyte peaks by the 
introduction of groups with fixed charges or easily ionisable groups (Zaiken and 
Halket 2006).
Whilst there are many derivatisation reagents available there is not a preferred 
universal reagent. Thus the choice is ultimately determined by the analytes of 
interest for the method of analysis. There are several requirements to consider 
when choosing the ideal derivatisation reagent for use in “soft” ionisation mass 
spectrometry: 1) the reagent should be pre-charged or include a group having 
high proton affinity, 2) it must contain a suitable reactive group and 3) preferably 
should be commercially available or synthesised using inexpensive reagents 
(Cartwright etal., 2005 and Zaikin and Halket 2006).
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Careful consideration should be made when selecting the derivatisation reagent 
for example smaller reagents are suited for sterically hindered functional 
groups, the addition of a larger reagent can have the desired effect of moving 
the mass of the derivative into the less noisy region of the mass spectrum 
(Vaiken and Halket 2009).
2.1.2. Derivatisation reagents
2.1.2.1.2.4-Dinitrophenvlhvdrazine
2.4-Dinitrophenylhydrazine (DNPH) is the most commonly used hydrazine 
based reagent for the purpose of derivatising the carbonyl functionalities of 
aldehydes and ketones for liquid chromatographic separation followed by 
UV/vis or fluorescence spectroscopy (Vogel et al., 2000). However the use of 
this reagent as a MALDI matrix requires caution. DNPH is reported to be 
explosive when dry (Sigma Aldrich MSDS). The structure of 2,4- 
dinitrophenylhydrazine is shown below in Figure 2.1.
N02
Figure 2.1: Structure of the hydrazine based reagent 2,4-
Dinitrophenylhydrazine (DNPH).
DNPH has been characterised as a "reactive matrix" this is because it not only 
derivatises the carbonyl containing compounds but also assists in ionisation and 
detection by MALDI-MS. DNPH was utilised in this capacity for the 
derivatisation and analysis of corticosteroids (Brombacher et al., 2003). The
HN*^NH2
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reaction between DNPH and the carbonyl groups of corticosteroids is shown 
below in Figure 2.2.
OH
OH
•NO;NO;
•Rie+
Figure 2.2: Scheme showing the reaction between steroids and DNPH to form 
the respective hydrazone derivative (Brombacher et al., 2003).
The derivatisation of glucocorticoids using DNPH results in the formation of the 
radical cation ([M]+‘) via charge transfer reactions. The intact derivatised steroid 
is also observed in the form of a protonated derivatised molecule ([Md+H]+) 
(Brombacher et al., 2003).
DNPH has recently been used for the derivatization of phospholipids and their 
related oxidation products for analysis by MALDI-MS (Teuber etal., 2012).
2.1.2.2. 4-Dimethvlamino-6-(4-methoxv-1-naphthvl)-1, 3. 5-triazine-2-hvdrazine 
4-Dimethylamino-6-(4-methoxy-1-naphthyl)-1, 3 , 5 -triazine-2 -hydrazine
(DMNTH) is a "tailor made" derivatisation reagent that combines a selective 
reactive functionality, stability and good spectroscopic properties in one 
compound (Mugo and Bottaro 2007). This reagent was developed by the Karst 
group at the University of Munster, Germany.
This reagent is synthesised by substitution reactions of cyanuric chloride, which 
acts as a base molecule to couple functional groups that have specific roles in 
the detection, reactivity and polarity of the derivatisation agent, this is illustrated 
in Figure 2.3.
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HN
‘OCH
S-triaz>ne ring of the base 
molecule cyanuric chloride 
(serves as the B A C K B O N E  
of the derivatisation reagent)
Hydrazine (N H N H .) attached  
via nucieophiltic substitution 
reaction (substituted functional 
group for R E A C T IV IT Y )
1 -Methoxynaphthalene ( Fluorophore) 
attached via Frieda I-Crafts alkylation 
reaction (substituted functional group 
for D E TE C TIO N )
Dimethylamine IW (C H -).i attached via 
nucleophi llic substitution reaction 
(substituted functional group for 
P O L A R IT Y )
Figure 2.3: Diagram showing the functional groups o f the derivatisation reagent 
4-Dimethylamino-6-(4-methoxy-1-naphthyl)-1,3,5-triazine-2-hydrazine (DMNTH) 
and their functions.
There are several reports of the use of DMNTH as a derivatisation reagent. 
Examples are the derivatisation of carbonyl containing compounds followed by 
chromatographic separation and detection by atmospheric pressure chemical 
ionisation (APCI) mass spectrometry (Kempter et al., 1999) and in water 
samples (Kempter and Karst 2000). The optimised parameters necessary for 
the separation of DMNTH derivatised carbonyl compounds by reversed phase 
capillary electrochromatography (CEC) were described by (Liu et al., 2001).
Test tubes coated with DMNTH have been used for the determination of 
aldehydes in air samples followed by chromatographic separation and detection 
by UV-visible and fluorescence spectroscopy, the results were found to be 
comparable to the established method using the derivatisation reagent DNPH 
(Kempter et al., 2002). The most recent application of DMNTH has been 
reported by (Mugo and Bottaro in 2007), for the derivatisation and analysis of a
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range of carbonyl containing compounds by laser desorption ionisation-mass 
spectrometry (LDI-MS).
2.1.2.3. Girard’s reagents
Girard’s reagent P (l-(carboxymethyl) pyridinium chloride hydrazide) and 
Girard’s reagent T (carboxymethyl) trimethylammonium chloride hydrazide) 
were first introduced by (Girard and Sandulesco in 1936).
Both reagents possess a permanently charged moiety which promotes a strong 
[M]+ ion for the derivative when analysed by mass spectrometry (Griffiths et al., 
2003). The structures of the Girard’s reagents are shown below in Figure 2.4.
Figure 2.4: Structures of the derivatisation reagents Girard’s reagent P (left) 
and Girard’s reagent T (right).
Girard’s reagents were first used by their discoverers to separate steroids such 
as esterone from urinary extracts (Wheeler 1962). Since then the Girard’s 
reagents have been extensively used for the isolation and identification of 
steroids in biological fluids.
The potential of using Girard’s reagents in doping control studies was 
demonstrated by (Shackleton et al., in 1997). In this work Girard’s reagent T 
was used for the derivatisation of testosterone esters that were extracted from 
plasma samples of volunteers, followed by high performance liquid 
chromatographic separation and analysis by ESI-MS.
Girard’s reagent P was successfully employed for the derivatisation of neutral 
oxosteroids to facilitate improved analysis and detection by both ESI-MS and
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MALDI-MS by (Griffiths et at., 2003). Girard’s reagent P was later used for the 
derivatisation of androgenic steroids (representative of those found during 
malpractice in the cattle industry) in spiked heifer urine followed by analysis by 
ESI-MS by (Kirk e ta i, 2006).
Girard’s reagent T has also been used in the derivatisation of oligosaccharides 
(Naven and Harvey 1996). Similarly Girard’s reagent T was used with a 
derivatisation reagent called glycidyltrimethylammonium chloride (GTMA) for 
the derivatisation of oligosaccharides by (Gouw et at., 2002).
1.3. Other applications of derivatisation in mass spectrometry
Recently a technique termed “reactive DESI” which involves the addition of 
reagents to the standard solvent spray for the purpose of derivatisating analytes 
present in the sample was introduced by (Eberlin et at., 2011).
This technique has been utilised for the derivatisation of anabolic steroids, using 
hydroxylamine to form oximes which enabled their detection in urine samples 
(Huang et at., 2007).
This method was utilised for the derivatisation of cortisone using a solvent 
spray containing the derivatisation reagent Girard’s reagent T (Girod et al., 
2011a). Another study demonstrated the use of “Reactive DESI” for the 
derivatisation and imaging of malondialdehyde (MDA) (an oxidative stress 
marker) in injured rat spinal cord tissue samples. This was achieved by the 
addition of the derivatsation reagent to the solvent spray (Girod et at., 2011b).
1.4. Aims and Objectives
The hydrazine based reagents DNPH, DMNTH and Girard’s reagent P have 
been employed for the derivatisation of a range of glucocorticoids both in­
solution and on-tissue to form their respective hydrazones and improve their
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mass spectral ionisation efficiency and detection. Fluticasone propionate has 
been selected to demonstrate each example
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2.2. Methods
2.2.1. Information
All animal studies were ethically reviewed and carried out in accordance with 
Animals (Scientific Procedures) Act 1986 and the GSK Policy on the Care, 
Welfare and Treatment of Laboratory Animals.
2.2.2. Materials
The reagents a-cyano-4-hydroxycinnamic acid (CHCA), fluticasone propionate, 
beclomethasone dipropionate, budesonide, trifluoroacetic acid (TFA) and 
ALUGRAM1 SIL G/UV254 precoated aluminum sheets were purchased from 
Sigma Aldrich® (Gillingham, Dorset, UK). The solvents methanol (MeOH), 
ethanol (EtOH) and acetonitrile (ACN) were purchased from Fisher Scientific 
(Loughborough, Leicestershire, UK). Girard's reagent P and dexamethasone 
was purchased from TCI Europe (Belgium). 2, 4-dinitrophenylhydrazine (DNPH) 
was purchased from Alfa Aesar®(Heysham, Lancashire, UK). 4-Dimethylamino- 
6-(4-methoxy-1-naphthyl)-1, 3, 5-triazine-2-hydrazine (DMNTH) was kindly 
donated by Professor Uwe Karst (University of Munster, Germany).
2.2.3. Instrumentation
Mass spectra and images were acquired in positive ion mode on an Applied 
Biosystems/MDS Sciex hybrid quadrupole time-of-flight mass spectrometer (Q- 
Star Pulsar-/) with an orthogonal MALDI ion source (Applied Biosystems, Foster 
City, California, USA) and a high repetition Neodymium-doped yttrium vanadate 
(Nd: YVO4) laser (5 KHz) (Elforlight Ltd, Daventry, Northamptonshire, UK). 
Image acquisition was performed at a spatial resolution of 150 pm x 150 pm in
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“Raster Image” mode; images were generated using the freely available 
Novartis Biomap 3.7.5.5 software (www.maldi-msi.org).
Other mass spectrometry measurements were performed on a Thermo 
Finnigan MAT LCQ Classic Electrospray Ionisation-Mass Spectrometer 
(Thermo Finnigan, San Jose, California, USA).
2.2.4. Tissue preparation
Frozen control rat lung tissue was sectioned using a Leica cryostat (Leica 
Microsystems, Wetzlar, Germany) to produce 12 pm thick sections, which were 
thaw mounted onto clean aluminium sheets.
2.2.5. Derivatisation of glucocorticoids using DNPH
2.2.5.1. In-solution derivatisation procedure
The derivatisation procedure involved the incubation of 10 pi of a test steroid 
(0.5 mg/ml in acetonitrile) and 10 pi of the solution of the DNPH matrix (1 mg/ml 
in acetonitrile with 0.3 % hydrochloric acid) in a 0.5 ml micro-centrifuge tube at 
room temperature for 30 minutes.
The derivatised steroids were then analysed using the Q-Star instrument 
operated in positive ion mode with an accumulation time of 0.7287 seconds 
(quoted as 4 decimal places from this point), declustering potential of 0, 
focusing potential of 20, second declustering potential of 15, collision gas of 3 
arbitrary units and the scanning duration of 1 minute with a mass range of m/z 
150-1000.
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2.2.5.2. On-tissue derivatisation procedure
Fluticasone proprionate (C25H31F3O5S, MW 500.57) standards (500, 100, 50, 25 
and 5 ng/pl prepared in 70 % acetonitrile) were spotted (1 pi) onto a control rat 
lung tissue section in triplicate. Then 1 pi of a 4 mg/ml solution of DNPH in 50: 
50 acetonitrile: water with 0.1 % TFA was applied onto the spiked areas (10 
times per spot and allowed to dry between applications).
Using the Labcyte Portrait 630™ reagent multispotter (Labcyte, California, USA) 
as described by (Aerni et al., 2006), the reactive matrix (4 mg/ml solution of 
DNPH in 50: 50 acetonitrile: water with 0.1 % TFA) was deposited onto the 
spiked lung tissue (20  cycles with 200  pm distance between spots).
Imaging experiments were performed using the Q-Star instrument with the 
“Raster Image” mode set to the "slow" speed, the instrument was operated in 
positive ion mode with an accumulation time of 0.2943 seconds, declustering 
potential of 0, focusing potential of 20, second declustering potential of 15, 
collision gas of 3 arbitrary units, ion release delay (IRD) of 67.1 (the width of the 
pulse of ions released by the collision cell into the TOF), ion release width 
(IRW) of 29.1, duration of scanning of 2 minutes and a mass range of m/z 150- 
700 with enhancement of m/z 500.2.
2.2.6. Derivatisation of glucocorticoids using Girard’s reagent P
2.2.6.1. In-solution derivatisation procedure
The conversion of steroids into their respective Girard P hydrazones was 
performed using the method reported by (Kirk etal., 2006). In summary, 300 mg 
of Girard's reagent P was weighed out and added to a 150 ml round bottom 
flask, to this 1 mg of the steroid was added along with 100 ml of methanol with 
10 ml of glacial acetic acid. The reaction mixture was warmed using an oil bath
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(70°C for 30 minutes), after which the reaction mixture was dried under a 
stream of nitrogen leaving a small amount of yellow oil, which was then 
reconstituted in 100 ml of a 10% methanol solution.
The derivatised steroids produced were analysed using a LCQ instrument 
operated in positive ion mode with a capillary temperature of 200°C, spray 
voltage of 4.50 kV and sheath gas flow (N2) 60 arbitrary units. The samples 
were introduced by direct infusion using the syringe pump on the instrument at 
a rate of 3 pl/minute‘1 and a mass range of 150-1000 was scanned. For tandem 
mass spectrometry experiments the collision energy was set to 32% in order to 
retain the precursor ions.
2.2.7. Derivatisation of glucocorticoids using DMNTH
2.2.7.1. In-solution derivatisation procedure
The derivatisation procedure involved the incubation of 10 pi of a test steroid (2 
mg/ml in acetonitrile) and 10 pi of the DMNTH matrix (5 mg/ml in 50: 50 
acetonitrile: water with 0.1 % TFA) in a 0.5 ml micro-centrifuge tube at room 
temperature 48 hours.
The derivatised steroids were analysed using the Q-Star instrument operated in 
positive ion mode with an accumulation time of 0.728655 seconds, declustering 
potential (DP) of 0, focusing potential (FP) of 20, second declustering potential 
(DP2) of 15, collision gas (CAD) of 3 arbitrary units and the scanning duration of 
1 minute with a mass range of m/z 250-900.
2.2.7.2. On-tissue derivatisation procedure
Fluticasone Proprionate standards (2000, 1000, 500, 250, 100, 50, 20 and 10 
ng/pl prepared in 70 % acetonitrile) were spotted (1 pi) onto a control rat lung
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tissue section. Using the Labcyte Portrait 630™ reagent multispotter, the 
reactive matrix (5 mg/ml solution of DMNTH in 50: 50 acetonitrile: water with 0.1 
% TFA) was deposited onto the spiked lung tissue (25 cycles with 200 pm spot- 
to-spot distance).
Once the spiked tissue section had been coated with the reactive matrix, it was 
placed onto a polystyrene block and placed into a glass chamber containing 50 
% methanol (Figure 2.5). The chamber lid was sealed using parafilm and 
incubated at 37°C with 5 % carbon dioxide for 48 hours in a Heraeus, Heracell 
incubator.
Polystyrene block MALDI plate with coated tissue
Glass contair
ip J vi j y  i f
Figure 2.5: Equipment setup for the incubation of the reactive matrix coated 
tissue.
Following incubation the section was analysed using the Q-Star instrument with 
the “Raster Image” mode set to the "slow" speed, the instrument was operated 
in positive ion mode with an accumulation time of 0.4886 seconds, declustering 
potential (DP) of 0, focusing potential (FP) of 20, second declustering potential 
(DP2) of 15, collision gas (CAD) of 3 arbitrary units, ion release delay (IRD) of
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84.5, ion release width (IRW) of 36.6, duration of scanning was 3 minutes and a 
mass range of m/z 450-800 with enhancement of m/z 793.2.
2.2.8. Data processing
Mass spectra from Analyst were exported in the form text files and imported into 
mMass, an open source mass spectrometry software used for mass spectral 
processing (Strohalm eta!., 2010).
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2.3. Results and Discussion
2.3.1. MALDI-MS analysis of glucocorticoids
To illustrate the challenge of analysing glucocorticoids with MALDI-MS, a 
solution of fluticasone propionate was mixed with the matrix CHCA and spotted 
onto a MALDI target plate. The resulting MALDI-MS spectrum is displayed 
below in Figure 2.6.
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Figure 2.6: MALDI-MS spectrum showing fluticasone propionate (500 ng/pl) 
mixed with the matrix CHCA. The spectrum shows the presence of matrix 
related peaks and the expanded region shows the sodium adduct of Fluticasone 
propionate ([M+Na]*) at m/z 523.1964.
The MALDI-MS spectrum displayed above in Figure 2.6 shows an abundance 
of CFICA matrix related peaks below 500 Da, the insert shows the sodium 
adduct ([M+Na]+) of Fluticasone propionate at m/z 523.1964. As previously 
mentioned glucocorticoids are not easily analysed in mass spectrometry 
because they lack sites to which a proton can be attached and as a result they 
are ionised by the addition of metal ions such as sodium or potassium but with 
low efficiency.
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2.3.2. In-solution derivatisation using DNPH
The MALDI-MS spectrum obtained for fluticasone propionate following 
derivatisation with DNPH is shown below in Figure 2.7.
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Figure 2.7: MALDI-MS spectrum showing fluticasone propionate (500 ng/pl) 
following 1 hour reaction with the reactive matrix DNPH at room temperature. 
The spectrum shows the presence of the radical cation ( [M f) of fluticasone 
propionate at m/z 500.1402, the sodium adduct ([M+Naf) at m/z 523.0986, the 
potassium adduct ([M+Kf) at m/z 539.0763 and the protonated hydrazone 
derivative ([Md+HJ*) at m/z 681.1208.
The MALDI-MS spectrum obtained (Figure 2.7) shows a radical cation ([M]+ ) at 
500.1402, the sodium adduct ([M+Na]+) at m/z 523.0986 (the most abundant 
ion), the potassium adduct ([M+K]+) at m/z 539.0763 and the protonated 
hydrazone derivative ([Md+H]+) of fluticasone propionate at m/z 681.1208. The 
spectrum also shows the presence of the protonated reactive matrix ([M+H]+) at 
m/z 199.0229.
During the analysis of derivatised corticosteroids, budesonide and
dexamethasone, (Brombacher et al., 2003) observed the presence of a strong
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sodium adduct ion signal ([M+Na]+) in addition to the radical cation and 
protonated hydrazone derivative. Also the intensity of the sodium adduct was 
found to be higher than that of the radical cation, which is also observed in the 
spectrum shown in Figure 2.7.
The MALDI-MS spectrum of fluticasone propionate following derivatisation with 
a mixture of CHCA and DNPH is shown below in Figure 2.8.
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Figure 2.8: MALDI-MS showing fluticasone propionate (500 ng/pl) following 1 
hour reaction with a mixture of the reactive matrix DNPH and CHCA at room 
temperature. The spectrum shows the presence of the radical cation ( [M f) of 
fluticasone propionate at m/z 500.1022, the sodium adduct ([M+Na]+) at m/z
523.0709, the potassium adduct ([M+K]+) at m/z 539.0473 and the protonated 
hydrazone derivative ([MD+H]+) at m/z 681.0750.
The MALDI-MS spectrum shown above in Figure 2.8 shows the radical cation 
([M]+) at 500.1022 (the most abundant ion), the sodium adduct ([M+Na]+) at m/z
523.0709, the potassium adduct ([M+K]+) at m/z 539.0473 and the protonated
hydrazone derivative ([MD+H]+) of fluticasone propionate at m/z 681.0750. The
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spectrum also shows a high abundance of CHCA related adduct ions below 500 
Da.
The spectrum shown in 2.8 highlights that the addition of CHCA to the DNPH 
has changed the ratio between the radical cation ([M]+ ) at m/z 500 and sodium 
adduct ([M+Na]+) at m/z 523 of fluticasone propionate. Also the spectrum shows 
the addition of CHCA appears to improve the intensity of the radical cation and 
the protonated hydrazone derivative ion by approximately a factor of 2.
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2.3.3. In-solution derivatisation using Girard’s reagent P
The ESI-MS spectrum of fluticasone propionate following derivatisation with 
Girard’s reagent P is shown below in Figure 2.9.
[ 150 .00 - 1000 .00 ]
Protonated hydrazone derivative ([M D
Un-reacted Girard's reagent P
Figure 2.9: ESI-MS spectrum showing fluticasone propionate following 
derivatisation with Girard’s reagent P at a temperature o f 70°C for 30 minute. 
The spectrum shows the protonated hydrazone derivative at m/z 634.2.
The ESI-MS spectrum depicted in Figure 2.9 shows the protonated hydrazone 
derivative of fluticasone propionate at m/z 634.2 and a peak at m/z 152.1 which 
fits for the un-reacted Girard’s reagent P.
To confirm the peak at m/z 634.1 is that of the protonated hydrazone derivative 
([M]+) of fluticasone propionate a tandem mass spectrometry experiment was 
performed to generate a product ion scan. The ESI-MS/MS spectrum obtained 
is illustrated in Figure 2.10.
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Product ion ([M-79]*)
Protonated hydrazone derivative 
([M]*) at m/z 634.1
'■'CH,
Product ion ([M-107]*)
Figure 2.10: ESI-MS/MS spectrum showing the product ions at m/z 527.1 and 
m/z 555.0, derived from the precursor ion o f the protonated hydrazone 
derivative at m/z 634.1.
The ESI-MS/MS spectrum shown in Figure 2.10 shows the product ions at m/z 
527A and m/z 555.0, derived from the precursor ion of the protonated 
hydrazone derivative of fluticasone propionate at m/z 634.1 confirming the 
identity of the hydrazone derivative. The resulting product ions designated, ([M- 
79]+) at m/z 555.0 is interpreted as the loss of the pyridine ring and a 
rearrangement to form the six membered dihydropyridazinone ring. The ion 
designated as ([M-107]+) at m/z 527.1 is interpreted as the loss of the carbonyl 
group and a rearrangement to form the five membered dihydropyrazole ring. 
The assignment of the product ions is based upon the work reported by 
(Shackleton et al., 1997) and is represented in the scheme in Figure 2.11.
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Figure 2.11: Simplified scheme showing the fragmentation o f Steroidal Girard P 
Hydrazones and the formation o f the six membered dihydropyridazinone ring 
and the five membered dihydropyrazole ring (Griffiths et al., 2008).
2.3.4. In-solution derivatisation using DMNTH
The MALDI-MS spectrum obtained for fluticasone propionate following 
derivatisation with DMNTH is shown below in Figure 2.12.
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Figure 2.12: MALDI-MS spectrum showing fluticasone propionate (500 ng/pl) 
following a 48 hour incubation with the reactive matrix DMNTH at room  
temperature. The spectrum shows the presence o f the protonated un-reacted  
DMNTH ([M+H]+) at m/z 311.1621 and the protonated hydrazone derivative 
([Md+Hf )  at m/z 793.3123.
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The MALDI-MS spectrum shown in Figure 2.12 shows the most abundant ion at 
m/z 793.3123 which fits for the protonated hydrazone derivative ([MD+H]+) of 
fluticasone propionate. Also present is the protonated un-reacted DMNTH 
([M+H]+) ion at m/z 311.1621.
Derivatising fluticasone proprionate with a mixture of CHCA and DMNTH gave a 
more complex spectrum (see Figure 2.13).
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Figure 2.13: MALDI-MS spectrum showing fluticasone propionate (500 ng/pl) 
following 48 hour reaction with a mixture o f the reactive matrix DMNTH and 
CHCA at room temperature. The spectrum shows the presence o f the 
protonated hydrazone derivative ([M o+Hf) at m/z 793.2853.
The MALDI-MS spectrum shown in Figure 2.13 shows the protonated 
hydrazone derivative ([MD+H]+) at m/z 793.2853 of fluticasone propionate. The 
spectrum also shows the presence of protonated un-reacted DMNTH ([M+H]+) 
at m/z 311.1434 which is the most abundant peak. The spectrum also shows 
the addition of CHCA improves the detection of the protonated hydrazone 
derivative by approximately a factor of 10.
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The results obtained from the in-solution derivatisation of all the glucocorticoids 
with the three hydrazine based derivatisation is shown below in Table 2.1.
<r>U>
<0
KJ to
'T
•n «•
Table 2.1: A table summarising the results from the in-solution derivatisation o f 
the glucocorticoids with the hydrazine based derivatisation reagents.
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2.3.5. On-tissue derivatisation using DNPH
Following the successful application of DNPH and DMNTH for the in-solution 
derivatisation of the range of glucocorticoids, the next step was to apply these 
reagents for on-tissue derivatisation experiments. The MALDI-MS images 
shown below in Figure 2.14 demonstrate the application of the reactive matrix 
DNPH for the derivatisation of fluticasone propionate on a control rat lung tissue 
section.
Figure 2.14: Optical images showing the spiked tissue section A) before and B) 
after reactive matrix deposition. MALDI-MS images showing the distribution of 
C) the radical cation ([M]+) of fluticasone propionate at m/z 500.2 and D) the 
protonated hydrazone derivative ([Md+H]*) of fluticasone propionate at m/z
681.2.
99
The MALDI-MS images displayed in Figure 2.14 shows the distribution of the 
radical cation ([M]+) m/z 500.2 and the protonated hydrazone derivative 
([Md+H]+) m/z 681.2 of fluticasone propionate within the spiked areas of the 
lung tissue. However, the lack of linearity of the response with respect to 
concentration spiked needs to be investigated further. The cause may be 
related to the compound spiking methods and / or matrix application.
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2.3.6. On-tissue derivatisation using DMNTH
The MALDI-MS images displayed below in Figure 2.15 shows the application of 
the reactive matrix DMNTH for the derivatisation of fluticasone propionate on a 
control rat lung tissue section without incubation prior to analysis.
Figure 2.15: Optical images showing the spiked tissue section A) before and B) 
after reactive matrix deposition. MALDI-MS images showing the distribution of 
the protonated hydrazone derivative of fluticasone propionate at m/z 793 C) 
before and D) after normalisation against the distribution of E) a reactive matrix 
related peak at m/z 589.
The MALDI-MS Images shown in Figure 2.15 shows the distribution of the 
protonated hydrazone derivative ( [ M d + H ] + ) at m/z 793.2, the distribution of the 
reactive matrix related peak at m/z 589.2 and the protonated hydrazone 
derivative ([MD+H]+) at m/z 793.2 following normalisation with the reactive 
matrix peak at m/z 589.2. The distribution of the protonated hydrazone 
derivative ([MD+H]+) at m/z 793.2 is within the spiked areas of the tissue and the
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normalised image shows that it is detectable down to 500 ng/pl following no 
incubation.
In contrast the MALDI-MS images presented below in Figure 2.16 shows the 
application of the reactive matrix DMNTH for the derivatisation of fluticasone 
propionate on a control rat lung tissue section. However this time the coated 
tissue section was incubated for 48 hours at 37°C prior to analysis, the reason 
for the incubation of the coated tissue is to maintain the derivatisation reaction 
on the sample surface.
Figure 2.16: Optical images showing the spiked tissue section A) before and B) 
after reactive matrix deposition. MALDI-MS images showing the distribution of 
the protonated hydrazone derivative of fluticasone propionate at m/z 793 C) 
before and D) after normalisation against the distribution of E) a reactive matrix 
related peak at m/z 589.
The MALDI-MS Images shown in Figure 2.16 shows the distribution of the 
protonated hydrazone derivative ([MD+H]+) at m/z 793.2, the distribution of the
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reactive matrix related peak at m/z 589.2 and the protonated hydrazone 
derivative ([Md+H]+) at m/z 793.2 following normalisation with the reactive 
matrix peak at m/z 589.2. The distribution of the protonated hydrazone 
derivative ([Md+H]+) at m/z 793.2 is within the spiked areas of the tissue and the 
normalised image shows that it is detectable down to 50 ng/pl following a 48 
hour incubation at 37°C.
As the MALDI-MS images presented in Figures 2.15 and 2.16 show incubation 
of DMNTH coated samples at 37°c for 48 hours improves the detection of the 
protonated hydrazone derivative by a factor of 10.
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The MALDI-MS presented below in Figure 2.17 shows the application of the 
reactive matrix DMNTH for the derivatisation of fluticasone propionate, 
beclomethasone dipropionate, budesonide and dexamethasone on a control rat 
lung tissue section. As in the previous experiment the coated tissue section was 
incubated at 37°C for 48 hours (prior to analysis).
Figure 2.17: Optical images showing the spiked tissue section A) before and B) 
after reactive matrix deposition. MALDI-MS images showing the distribution of 
the protonated hydrazone derivatives of C) fluticasone propionate at m/z 793, 
D) beclomethasone dipropionate at m/z 813, E) budesonide at m/z 723, F) 
dexamethasone at m/z 685 all images were normalised against the distribution 
of G) a reactive matrix related peak at m/z 589.
The MALDI-MS images shown in Figure 2.17 shows the distribution of the 
protonated hydrazone derivatives ([Md+H]+) of the four steroids on-tissue 
following incubation for 48 hours at 37°C. The detection of the protonated 
hydrazone derivatives of fluticasone propionate at m/z 793, beclomethasone 
dipropionate at m/z 813, budesonide at m/z 723 and dexamethasone at m/z 685
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was observed within the respective spiked areas on the tissue. This experiment 
shows DMNTH is capable of derivatising all the steroids under study on-tissue.
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2.4. Conclusions
The use of hydrazine based reagents has successfully been employed for the 
derivatisation of glucocorticoids to form their respective hydrazones (both in­
solution and on-tissue) and thus improve their mass spectral ionisation 
efficiency and detection.
Girards’s reagent P was successfully used for the in-solution derivatisation of 
glucocorticoids, without a lengthy preparation time (-30 minutes). The 
quaternary nitrogen within the pyridine ring structure, produced a hydrazone 
derivative which was readily detected by mass spectrometry. Whilst the 
preparation time was only 30 minutes, Girard's reagent P was considered 
unsuitable for on-tissue experiments due to the high temperatures (~70°C) 
required to produce the hydrazone derivatives. The high temperatures would 
have a detrimental effect on the tissue and its constituents.
The use of DNPH for in-solution derivatisation of glucocorticoids was successful 
and the reaction with the glucocorticoids was found to be quick (-30 minutes), 
however it was found that the other glucocorticoids such as beclomethasone 
dipropionate and budesonide required a longer reaction time (-24 hours) in 
order to produce a detectable signal possibly due to the differences in the 
structures affecting the reaction kinetics.
The application of DNPH to the on-tissue experiments was also successful, the 
presence of the radical cation ([M]+ ) and the protonated hydrazone derivative 
([M d+ H ]+) of fluticasone propionate was observed in the spiked areas of the 
tissue sections. However further studies are required for the application of 
DNPH to on-tissue experiments to explain the apparent lack of linearity for the 
response with respect to concentration spiked onto the tissue section, which
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could possibly be due to the application of the reactive matrix onto the spiked 
tissue section.
The tailor made reactive matrix DMNTH has successfully been applied to the in­
solution derivatisation of glucocorticoids. It has been shown that a prolonged 
reaction (~48 hours) improves the detection of the protonated hydrazine 
derivative. The application of DMNTH to on-tissue experiments has also been 
successful, it has been shown that analysis of samples immediately after 
reactive matrix application results in the detection of the protonated hydrazone 
derivative ([Md+H]+) of fluticasone propionate at concentration of 500 ng/pl. It 
was found that following incubation in a humid environment (37°C) results in the 
detection of the protonated hydrazone derivative ([Md+H]+) of fluticasone 
propionate at a concentration of 50 ng/pl.
Further improvements in sensitivity and limits of detection were observed when 
CHCA was added to the reactive matrices DNPH or DMNTH.
Based on these observations, it is recommended to use Girard’s reagent P for 
the in-solution derivatisation of corticosteroids. This is due to the quick reaction 
time and the well documented product ion formation, which results in easier 
tandem mass spectral interpretation and compound identification. For the on- 
tissue applications it is recommended to use the reactive matrix DMNTH, this is 
due to the presence of a strong protonated hydrazone derivative being the only 
species observed that is related to the derivatised corticosteroid, which is not 
the case with the reactive matrix DNPH.
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Chapter 3
Monitoring the distribution of respiratory compounds in the lungs by MALDI-MSI
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3.1. Introduction
3.1.1. Traditional methods of drug analysis in tissue sections
3.1.1.1. Whole Body Autoradiography
Whole Body Autoradiography (WBA) is a technique that monitors the spatial 
distribution of radiolabelled compounds within whole body tissue sections and is 
commonly used during the early stages of drug discovery and development 
(Trim et a/., 2009). This technique is also a mandatory procedure for drug 
approval by the Food and Drug Administration (FDA).
Briefly, the technique involves the administration of a radiolabelled compound 
(commonly 14C or 3H) to a laboratory animal (usually a rat), which is sacrificed a 
defined time post dose based on the compound's known pharmacokinetics. The 
intact carcass is snap-frozen, embedded in a frozen carboxymethylcellulose, 
and cryosectioned (Solon and Kraus 2001). Whole-body sections are then 
exposed to a radioactivity detector (x-ray film or phosphor imaging plates) which 
allows the visualisation of the spatial distribution of the radiolabelled compound. 
An example of the data produced by this technique is illustrated by two whole 
body autoradiograms shown in Figure 3.1.
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5 minutes post d o se
Intestine
StomachLiver
Figure 3.1: Whole body autoradiograms showing the distribution of 14C- 
testosterone throughout the whole body section of a rat following intravenous 
administration, sacrificed 5 minutes and 2 hours post dose.
The advantages of this technique are parallel sample processing, standardised 
procedures, high sensitivity, and quantification (Stoeckli et al., 2007). However, 
the disadvantages of this technique are that it requires the use of a 
radiolabelled candidate which is often expensive to synthesise and the inability 
to distinguish between the parent compound and metabolites.
3.1.1.2. Liquid Chromatoqraphv-Tandem Mass Spectrometry 
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) can be used 
as a complement to WBA, it involves the excision of individual organs that are 
homogenised followed by extraction procedures. The extracts are then 
analysed by LC-MS/MS to determine the metabolites of a given compound, 
however during sample preparation the spatial distribution of the parent 
compound and metabolites is lost (Wang etal., 2005).
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3.1.2. Mass Spectrometry Imaging
3.1.2.1. Matrix-Assisted Laser Desoprtion/lonisation-Mass Spectrometry 
Imaging
Matrix-Assisted Laser Desoprtion/lonisation-Mass Spectrometry Imaging 
(MALDI-MSI) is a label free technique that can simultaneously measure the 
distribution of both parent compound and metabolites throughout tissue 
sections.
The use of MALDI-MSI in pharmaceutical research has been on-going for over 
a decade and is currently being employed by some pharmaceutical companies 
as a complementary technique to QWBA and LC-MS/MS.
3.1.2.2. MALDI-MSI in monitoring drug distribution
The first demonstration of the application of MALDI to directly study 
pharmaceutical compounds in animal tissue was reported by (Troendle et al., in 
1999). In this work the anticancer drug paclitaxel was detected in ovarian tumor 
xenografts and the antipsychotic drug spiperone was detected in spiked liver. 
However imaging experiments were not conducted in this work.
The first true MALDI-MSI experiment to monitor the distribution of 
pharmaceutical compounds in biological tissue sections was reported by 
(Reyzer et al., 2003). In this work MALDI-MSI was applied to monitoring the 
distribution of a candidate antitumor drug (SCH226374) throughout a rat brain 
and tumour tissue sections.
Following these demonstrations the MALDI-MSI technique has been applied to 
monitoring the distribution of a wide range of pharmaceutical compounds 
throughout various tissues and is still used to this day (Prideaux and Stoeckli 
2012).
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The use of both MALDI-MSI and WBA techniques in mapping the distribution of 
the antipsychotic drug clozapine using these techniques was demonstrated by 
(Hsieh et al., 2006). The resulting images revealed that the data from both 
techniques complemented each other.
MALDI-MSI was first applied to monitoring the distribution of a pharmaceutical 
compound throughout a whole-body tissue section in a mouse by (Rohner et al., 
2005). The resulting images showed the compound to be localised within the 
brain of the mouse.
This work was followed by a more in-depth study by (Stoeckli et al. 2007) and 
showed the distribution of an intra-tracheally administered compound 
throughout the whole-body tissue section of a rat. The images from MALDI-MSI 
and WBA show that after 5 minutes the compound is localised mainly within the 
trachea as expected and the stomach and after 1 hour the compound is 
localised within the nasal turbinates and the intestines.
The distribution of both parent compound and metabolites throughout whole- 
body tissue sections was reported by (Khatib-Shahidi et al. 2006) and showed 
the distribution of olanzapine and its metabolites throughout the whole-body 
tissue sections of a rat. These images showed high levels of olanzapine in the 
target organ (the brain) and two metabolites, A/-desmethylolanzapine and 2- 
hydroxymethyl olanzapine which were detected within liver, kidney and bladder 
tissues indicating metabolism and excretion of the drug.
Recently, the use of ion mobility separation with MALDI-MS imaging to monitor 
the distribution of the anti-cancer drug vinblastine throughout the whole-body 
section of a rat following intravenous administration was demonstrated by (Trim 
et al., 2009). These images showed that the distribution of vinblastine was 
within the liver and kidney. The utilisation of ion mobility separation allowed the
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separation of vinblastine and its metabolites from interfering isobaric ions 
associated with endogenous species, thus increasing the confidence in the data 
obtained.
3.1.3. Aims and objectives
The aim of this study was to determine, for a set of respiratory compounds, the 
feasibility of analysing them by MALDI-MS imaging and to determine their on- 
tissue limit of detection. Then to monitor the distribution of a selected respiratory 
compound throughout the lungs following inhaled delivery by MALDI-MSI. A 
comparison of the datasets obtained from the analysis of samples on different 
instruments was also undertaken.
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3.2. Methods
3.2.1. Information
All animal studies were ethically reviewed and carried out in accordance with 
Animals (Scientific Procedures) Act 1986 and the GSK Policy on the Care, 
Welfare and Treatment of Laboratory Animals.
3.2.2. Materials
Alpha-cyano-4-hydroxycinnamic acid (CHCA), 2, 5-dihydroxybenzoic acid 
(DHB), ipratropium bromide, formoterol fumarate dihydrate and trifluoroacetic 
acid (TFA) were purchased from Sigma Aldrich (Gillingham, Dorset, UK). 
Methanol (MeOH) was purchased from Fisher Scientific (Loughborough, 
Leicestershire, UK). The respiratory compounds ambroxol, amiloride, 
budesonide, fluticasone furate, fluticasone propionate, flunisolide, formoterol, 
indacaterol, ipratropium bromide, lidocaine, nedocromil, salbutamol, tacrolimus 
and tiotropium bromide were kindly provided by GlaxoSmithKline (Stevenage, 
UK).
3.2.3. Dose preparation and administration
The compound tiotropium was prepared by weighing out 1 mg of the compound 
into a large scintillation vial to which 4 ml of saline was added to make a 
0.25mg/ml solution. 1 ml of the saline vehicle was placed into a large 
scintillation vial for use as a control. Three Wistar Han rats (male) were dosed 
under a light anaesthesia of 1 L/min O2, 2 L/min NO2 and 5% isoflurane. The 
animals were held at a 45° angle for dosing and 200 pL of the dose was 
administered to the trachea 2-3 mm above the bifurcation point using a custom 
made IT dosing needle.
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The rats were then sacrificed immediately after dosing and 15 minutes post 
dose, the vehicle control rat was also sacrificed 15 minutes post.
The 200 pg/kg dose level was selected so as to deliver a 50 pg topical dose 
of compound to the lung, to emulate the lung dose given in the published 
data (Nilsson etal., 2010).
3.2.4. Tissue preparation
The frozen rat lung tissue was mounted to a cryostat stage using a 1% w/v 
solution of carboxymethylcellulose in water. The frozen tissue was sectioned 
using a Leica CM3050 cryostat (Leica Microsystems, Wetzlar, Germany) to 
produce 16 pm thick sections. The sections were transferred and thaw-mounted 
onto indium tin oxide coated glass slides (Bruker Daltonics, Bremen, Germany) 
for analysis on the Ultraflex series of mass spectrometers or onto conventional 
glass microscope slides for the other SYNAPT and QSTAR instruments. The 
glass slide was then optically scanned in a Nikon Super CoolScan 500ED 
scanner fitted with a MA-21 slide-mount adapter (Nikon Corporation, Tokyo, 
Japan) to produce a digital image.
3.2.5. Matrix deposition
The tissue sections were coated either with 7 mg/ml CHCA in 70:30 MeOH: 
H2O with 0.2 % TFA or 20 mg/ml DHB in 50:50 MeOH: H2O with 0.2 % TFA 
using the ImagePrep matrix application device (Bruker Daltonics, Bremen, 
Germany). Tissue sections were also coated with 5 mg/ml CHCA in 70:30 
MeOH: H2O with 0.2% TFA using the Suncollect™ automated pneumatic 
sprayer (Sunchrom, Friedrichsdorf, Germany) in a series of layers. The initial 
seeding layer and subsequent layers were performed at 10 pl/minute.
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3.2.6. Instrumentation
3.2.6.1. MALDI-LIFT-MS/MS imaging
Analyses were performed on an Ultraflextreme MALDI-TOF/TOF mass 
spectrometer (Bruker Daltonics) equipped with smart beam technology, a more 
detailed description was described by (Holle et al., 2006). The digital image of 
the sections was imported into Flexlmaging software (Bruker Daltonics), and 
through the software the instrument was taught the dimensions of the sections. 
The instrument was operated in LIFT MS/MS mode configuration with a 
potential of 19.10kV. The spatial resolution was run at 200 pm x 200 pm, with 
typical laser spot diameters of 75-80 pm. The MS/MS data was acquired in the 
m/z range between 100 and 500. The acquisition method was calibrated using a 
peptide calibration mixture (Bruker Daltonics) before the start of the experiment. 
MS/MS data was automatically acquired using the Flexlmaging software from a 
total of 200 spectra acquired at each spot position using the proprietary random 
walk mode in four 50-shot increments at a laser frequency of 1000Hz (Marshall 
et al., 2010).
3.2.6.2. MALDI-MS and MS/MS imaging
Mass spectra and images were acquired in positive ion mode on an Applied 
Biosystems/MDS Sciex hybrid quadrapole time-of-flight mass spectrometer (Q- 
Star Pulsar-/) with an orthogonal MALDI ion source (Applied Biosystems, Foster 
City, California, USA) and a high repetition Neodymium-doped yttrium vanadate 
(Nd: YVO4) laser (5 KHz) (Elforlight Ltd, Daventry, Northamptonshire, UK) a 
more detailed description is described elsewhere (Trim et al., 2010). Image 
acquisition was performed at a spatial resolution of 150 pm x 150 pm in “Raster
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Image” mode (Simmons 2008); images were generated using the freely 
available Novartis Biomap 3.7.5.5 software (www.maldi-msi.org).
3.2.6.3. MALDI-IMS-MS imaging
A Waters MALDI HDMS SYNAPT™ G2 mass spectrometer (Waters 
Corporation, Manchester, UK) was used to acquire mass spectra and images. 
Prior to MALDI-IMS-MSI analysis the samples were optically scanned using a 
CanoScan 4400F flatbed scanner (Canon, Reigate, UK) to produce a digital 
image for future reference, this image was then imported into the MALDI 
imaging pattern creator software (Waters Corporation) to define the region to be 
imaged. The instrument was calibrated prior to analysis using a standard 
mixture of polyethylene glycol (Sigma Aldrich). The instrument was operated in 
sensitivity mode and positive ion mode, all data was acquired with ion mobility 
separation in the mass range m/z 100 to 1000. The data was then converted 
using MALDI imaging converter software (Waters Corporation) and visualised 
using BioMap 3.7.5.5 software.
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3.3. Results and Discussion
3.3.1. Respiratory compound feasibility study
The purpose of the feasibility study was to screen a series of respiratory 
compounds to determine the on-tissue limit of detection. To begin serial 
dilutions of each compound were prepared and 1 pi was spotted onto a 
stainless steel target plate, MS and MS/MS profiles were then obtained. 
Following this a dilution series of each compound was spotted onto a control rat 
lung tissue section and MALDI-LIFT-MS/MS imaging was performed.
A selection of the results obtained and later a summary of the results for all the 
respiratory compounds will be shown.
The MALDI-MS spectrum of tiotropium is shown below in Figure 3.2.
Tiotropium ([M ]+)
Figure 3.2: MALDI-MS spectrum showing tiotropium ([M']*) at m/z 392.116 at a 
concentration of 100 ng/pl.
The MALDI-MS spectrum of tiotropium bromide obtained from a stainless steel 
MALDI target plate, is shown in Figure 3.2. The spectrum revealed a strong 
peak at m/z 392.116 that is clearly visible due to the positively charged nitrogen 
in the compounds structure.
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The MALDI-LIFT-MS/MS spectrum of tiotropium is shown below in Figure 3.3.
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Figure 3.3: MALDI-LIFT-MS/MS spectrum showing the product ions at m/z 
152.042 and m/z 170.113, derived from the precursor ion of tiotropium at m/z 
392 at a concentration of 100 ng/pl.
The MALDI-LIFT-MS/MS spectrum show in Figure 3.3 shows two product ions 
at m/z 152.042 and 170.113, derived from the precursor ion of tiotropium at m/z 
392.
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The MALDI-LIFT-MS/MS image of the tiotropium dilution series spotted on
tissue is shown below in Figure 3.4.
200 pg/pl
Figure 3.4: MALDI-LIFT-MS/MS image showing the distribution of the product 
ion at m/z 152, derived from the precursor ion of tiotropium at m/z 392 (200 pm 
spatial resolution).
The MALDI-LIFT-MS/MS image in Figure 3.4 shows the distribution of the 
product ion at m/z 152, derived from the precursor ion of tiotropium at m/z 392 
to be within the spiked areas on the tissue section. The image shows no 
interference from the tissue as there is no signal from the blank and the 
approximate on-tissue limit of detection of tiotropium is 20 pg/pl.
124
The ESI-MS/MS spectrum of tiotropium is shown below in Figure 3.5.
Figure 3.5: ESI-MS/MS spectrum showing the product ions at m/z 152.2 and 
170.2, derived from the precursor ion of tiotropium at m/z 392.2 (100 ng/ml).
The ESI-MS/MS spectrum shown in Figure 3.5 shows the product ions at m/z
152.2 and 170.2, derived from the precursor ion of tiotropium at m/z 392.2. The 
structure of the product ions was determined using Mass Frontier 5.1 software. 
The two product ions also match those seen in the MALDI-LIFT-MS/MS 
spectrum.
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One of challenges in the analysis of low molecular weight compounds by 
MALDI-MS is spectral noise in the low mass region due to matrix related peaks 
causing isobaric interference (Krutchinsky and Chait 2002). However with 
careful matrix selection and sample preparation this problem can be overcome. 
Isobaric interference was observed for the analysis of one of the respiratory 
compounds, ambroxol. This compound contains two bromines and there should 
be a cluster of peaks with a characteristic 1:2:1 ratio, which should be 
separated by 2 Da (Due to the bromine isotopic distribution for a compound that 
contains two bromines). There was a peak observed at m/z 379, which was 
initially thought to be the most abundant ion in this cluster of peaks.
However ambroxol was initially analysed using the matrix CHCA which when 
analysed also has a peak at m/z 379 related to the matrix dimer ([2M+H+), this 
isobaric interference was confirmed by MS/MS. Therefore the compound was 
analysed using the matrix DHB the mass spectrum of which is shown below in 
Figure 3.6.
Ambroxol ([M +H]+)
Figure 3.6: MALDI-MS spectrum showing ambroxol (100 ng/pl) analysed using
the matrix 2,5-Dihydroxybenzoic acid (DHB). The spectrum shows the presence 
of a peak at m/z 379.025.
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The MALDI-MS spectrum shown in Figure 3.6 shows a peak at m/z 379.025 the 
isotopic distribution of this peak shows the compound could possibly have two 
bromines in structure, which confirms this is the ambroxol ([M+H]+).
The MALDI-LIFT-MS/MS spectrum of ambroxol is shown below in Figure 3.7.
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Figure 3.7: MALDI-LIFT-MS/MS spectrum showing the product ions at m/z 
115.736 and 263.955, derived from the precursor ion of ambroxol at m/z 
379.025 (100 ng/pl).
The MALDI-LIFT MS/MS spectrum shown in Figure 3.7 shows two product ions 
at m/z 115.736 and 263.955, derived from the precursor ion of ambroxol at m/z 
379.025. The product ion at m/z 263.955 has the same isotopic distribution as 
previous shown in the mass spectrum as shown in Figure 3.6, indicating the 
presence of two bromine atoms.
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The MALDI-LIFT-MS/MS image of the ambroxol dilution series spotted onto a
control rat lung tissue section is shown below in Figure 3.8.
Figure 3.8: MALDI-LIFT-MS/MS image showing the distribution of the product 
ion at m/z 264, derived from the precursor ion of ambroxol at m/z 379.
The MALDI-LIFT-MS/MS image shown In Figure 3.8 shows the distribution of 
the product ion at m/z 264 derived from the precursor ion of ambroxol at m/z 
379 to be located within all of the spiked areas on the tissue section. The lack of 
signal in the blank region indicates image shows no interference from the 
tissue, approximate on-tissue limit of detection is 10 ng/pl.
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The ESI-MS/MS spectrum of ambroxol is shown below in Figure 3.9.
Figure 3.9: ESI-MS/MS spectrum showing the product ions at m/z 116.2 and 
264.0, derived from the precursor ion of ambroxol at m/z 379.1 (1 pg/ml).
The ESI-MS/MS spectrum shown in Figure 3.9 shows the product ions at m/z
116.2 and 264.0, derived from the precursor ion of ambroxol at m/z 379.1. The 
structure of the product ions was determined using Mass Frontier 5.1 software. 
The data supports the previous observation in the MALDI-MS/MS spectrum that 
the product ion at m/z 264 contains two bromines, the two product ions also 
match those seen in the MALDI-LIFT-MS/MS spectrum.
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The results from the feasibility study of the all the respiratory compounds are 
shown below in Table 3.1.
Compound Nam e (IU PA C ) Compound Structure Formula Monoisotopic Mass On-tissue LOD
Ambroxol
/rans-4-(2-Amino-3,5-dibrom benzylamino)- 
cyclohexanol
Br
C ,3H ieBr2N20 375.978585 10 ng/pL
Amiloride
3,5-diam ino-6-chloro-N-
(diaminomethylidene)pyrazine-2-carboxamide
" x x ;v . CfiHeCIN/O 229.047886 5 ng/pL
Formoterol
N-[2-hydroxy-5-( 1 -hydroxy-2-{[1 -(4 - 
methoxyphenyl)propan-2- 
yl]amino}ethyl)phenyl]formamide
jjT
f
CieH24N 204 344.173608 1 ng/pL
Indacaterol
5-[(1R )-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2- 
yl)amino]-1-hydroxyethyl]-8-hydroxy-1,2- 
dihydroquinolin-2-one
C24H28N20 3 392.209993 1 ng/pL
Ipratropium Bromide
(1 R ,3R ,5S,8R )-3-[(3-hydroxy-2- 
phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)- 
8-azabicyclo[3.2.1 ]octan-8-ium bromide
j— ' N —  CH-3 y -----O
** ^  HLO ' — o
C 2oH3oBrN03
411.140905
33 2.222569 (Observed  
as free base form)
0 .02 ng/ pL
Lidocaine
2-(diethylamino)-N-(2,6-
dimethylphenyl)acetamide T r "
C i 4H 22N 20 23 4.173213 5 ng/pL
Nedocromil
9-ethyl-4,6-dioxo-10-propyl-4H,6H,9H- 
chromeno[7,6-b]pyridine-2,8-dicarboxylic acid
C ,0H i 7N O 7 371.100504 10 ng/pL
Salbutamol
4-[2-(tert-butylamino)-1-hydroxyethyl]-2-
(hydroxymethyl)phenol CM,
c 13h 2,n o 3 239.152144 10 ng/pL
Tiotropium Bromide
(1R,2S,4R,5S)-7-{[2-hydroxy-2,2-bis(thiophen- 
2-yl)acetyi]oxy}-9,9-dimethyl-3-oxa-9- 
azatricyclo[3.3.1.0A{2,4}]nonan-9-ium bromide
C ieH22BrN04S2
471.017364
392.099028 (Observed  
as free base form)
0 .02 ng/ pL
Table 3.1: A table summarising the results from the feasibility study on a range 
of respiratory compounds and the determined on tissue limit of detection.
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3.3.2. MALDI-MS and MS/MS imaging of tiotropium in lung tissue sections
From the results obtained from the feasibility study it was clear that the 
anticholinergic bronchodilators ipratropium and tiotropium were the best 
candidates for further study, however the latter was chosen based on recently 
published data (Fehniger et at., 2011, Nilsson et al., 2010).
3.3.2.1. MALDI-MS and MS/MS images
The MALDI-MS and MS/MS images of tiotropium from consecutive rat lung 
tissue sections performed on the Q-Star mass spectrometer are shown below in 
Figure 3.10.
B) Section 12A) Section 10
E) Section 18D) Section 17C) Section 14
Figure 3.10: MALDI-MS and MALDI-MS/MS Images showing the distribution of 
A) product ions at m/z 152 and 170, B) product ions at m/z 152 and 170, C) 
product ions at m/z 152 and 170, D) tiotropium ([M]+) at m/z 392 and E) product 
ion at m/z 152 (Spatial resolution 100 pm).
The MALDI-MS and MS/MS images shown in Figure 3.10 shows the distribution 
of tiotropium ([M]+) at m/z 392 and the product ions at m/z 152 and m/z 170,
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derived from the precursor ion of tiotropium at m/z 392. The images show the
compound is localised in the trachea and major airways.
3.3.2.2. MALDI-IMS-MS images
The MALDI-IMS-MS images from a rat lung tissue section acquired on the
SYNAPT instrument are shown below in Figure 3.11.
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Figure 3.11: MALDI-IMS-MS Images showing the distribution of tiotropium 
([M f) at m/z 392 (green) in relation to endogenous species (red) such as A) 
phosphocholine at m/z 184, B) unidentified species at m/z 241, C) unidentified 
species at m/z 478, D) heme group of haemoglobin at m/z 616, E) unidentified 
species at m/z 710, F) unidentified species at m/z 772, F) unidentified species 
at m/z 380, G) unidentified species at m/z 872 and H) choline at m/z 104 
(Spatial resolution 100 pm).
The MALDI-MS images displayed in Figure 3.11 shows the distribution of 
tiotropium ([M]+) at m/z 392 (green). The images show the compound is 
localised in the trachea and major airways. The images showing the distribution 
of the compound have been overlaid onto other MALDI-MS images showing the
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distribution of endogenous species (red), to show the location of the drug in 
relation to the different sub-structures of the lungs, for example the image 
shown in Figure 3.11G shows the distribution of an unidentified peak at m/z 872 
which appears to be related to the cartilaginous rings of the trachea and major 
airways.
3.3.2.3. MALDI-LIFT-MS/MS images
The MALDI-LIFT-MS/MS images of consecutive rat lung tissue sections taken 
immediately after dosing are shown below in Figure 3.12.
Figure 3.12: MALDI-LIFT-MS/MS Images showing the distribution o f the 
product ion at m/z 152, derived from the precursor ion o f tiotropium at m/z 392. 
Consecutive sections showing A) section 11, B) section 12, C) section 15, D) 
section 16, E) section 17 and F) section 18 (Spatial resolution 200 pm).
The MALDI-LIFT-MS/MS images shown in Figure 3.12 shows the distribution of 
the product ion at m/z 152, derived from the precursor ion of tiotropium at m/z 
392 throughout consecutive tissue sections. Again the images shows the 
compound is localised in the trachea and major airways, the distribution of drug
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was overlaid onto the corresponding optical images to show the localisation of 
the compound within the tissue section.
3.3.3. High spatial resolution imaging of tiotropium in lung tissue sections
3.3.3.1. MALDI-IMS-MS images
Following analysis of the lung tissue section, areas of interest were selected 
and high spatial resolution imaging experiments (30 pm) were conducted on 
regions corresponding to the trachea and major airways of consecutive tissue 
sections, to obtain more detailed information on the drug distribution in these 
areas. The high spatial resolution MALDI-IMS-MS images of the trachea and 
major airway aquired on the SYNAPT instrument are shown below in Figure 
3.13.
Figure 3.13: MALDI-IMS-MS Images showing the distribution o f tiotropium  
( [M f) at m/z 392 (green) in relation to the endogenous species at m/z 872 (red). 
(30 pm spatial resolution).
The high spatial resolution MALDI-MS images displayed in Figure 3.13 shows 
the distribution of tiotropium ([M]+) at m/z 392 (green) overlaid onto the 
distribution of an unknown endogenous component at m/z 872 (red) that was
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localised in the cartilage rings of the trachea and airways. The images were 
normalised against the protonated CHCA matrix ([M+H]+) at m/z 190.
3.3.3.2. MALDI-LIFT-MS/MS images
The high spatial resolution (30 pm) MALDI-LIFT-MS/MS images of the trachea 
and major airway of rat lung tissue aquired on the UltrafleXtreme instrument are 
displayed below in Figure 3.14.
Figure 3.14: MALDI-LIFT-MS/MS images showing the distribution o f the 
product ion at m/z 152, derived from the precursor ion o f tiotropium at m/z 392 
throughout A) the major airway and B) the trachea (30 pm spatial resolution).
The high spatial resolution (30 pm) MALDI-LIFT-MS/MS images shown in 
Figure 3.14 shows the distribution of the product ion at m/z 152, derived from 
the precursor ion of tiotropium at m/z 392 within the trachea and major airways,
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the distribution of drug was overlaid onto the corresponding optical images. The 
image shown in Figure 3.14A shows the drug in the major airway and the image 
shown in Figure 3.14B demonstrate the compound is localised in the trachea 
but it appears the drug has begun to diffuse into the surrounding tissue.
3.3.3.3. MALDI-MS/MS images
The high spatial resolution (50 pm) MALDI-MS/MS images obtained on the 
QSTAR instrument of the trachea are shown below in Figure 3.15.
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Figure 3.15: MALDI-MS/MS images showing A) the distribution o f the product 
ion at m/z 152, derived from the precursor ion o f tiotropium at m/z 392. The 
distribution o f the compound is localised in the trachea immediately after 
intratracheal dosing. The expanded images show B) the data presented prior to 
smoothing and C) following smoothing (50 pm spatial resolution).
The high spatial resolution (50 pm) MALDI-MS/MS images shown in Figure 3.15 
shows the distribution of the product ion at m/z 152, derived from the precursor 
ion of tiotropium at m/z 392 within the trachea. The image shown in Figure 
3.15A shows the distribution of the product ion at m/z 152 throughout the 
trachea, the expanded images shown in Figures 3.15B and C shows the 
selected region before and after smoothing respectively.
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3.4. Conclusions
The feasibility study utilising MALDI-MS, LIFT-MS/MS and MSI has enabled the 
screening of a number of respiratory compounds and has provided information 
on the on-tissue limits of detection and appropriate matrix to be used for 
analysis. This information was then used to select the most appropriate 
respiratory compound in this case tiotropium bromide for further study, this 
compound was also selected based on recently published data.
One of the challenges with the use of MALDI-MSI in the analysis of 
pharmaceutical compounds is matrix related peaks causing interference, which 
was observed with the analysis of ambroxol. In the case of this study careful 
matrix selection was used to solve this problem.
MALDI-MS and MS/MS imaging has successfully been utilised to show the 
distribution of the anticholinergic bronchodilator tiotropium throughout the lungs 
following intratracheal delivery. The drug was found to be localised with the 
trachea and major airways immediately after dosing. High spatial resolution 
imaging has enabled a detailed view of the distribution of tiotropium in these 
areas.
The data sets obtained from the analysis of samples on three different types of 
instruments correlated well with each other. However due to problems with 
tissue sectioning of the 15 minute post dose rat lung tissue no data was 
obtained.
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Chapter 4
Development of methodology for the quantitation of pharmaceuticals in tissue 
sections by MALDI-MSI
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4.1. Introduction
4.1.1. Traditional methods for the quantitation of drugs in tissue sections 
4.1.1.1 Quantitative Whole Body Autoradiography
Quantitative whole body autoradiography (QWBA) is an extension of the WBA 
technique discussed earlier in Chapter 3, which monitors the distribution of a 
radio-labelled compound throughout whole body tissue sections of a rat. 
Quantitation is achieved using commercially available radiolabelled standards 
or using the method developed by (Schweitzer et a/., 1987) in which whole 
blood is spiked with serial dilutions of the radio-labelled compound and 
embedded in carboxymethylcellulose with the animal, as shown below in Figure
4.1.
*4 I *
Figure 4.1: Whole body autoradiogram showing the distribution o f a radio­
labelled compound throughout the whole body section o f a rat. The highlighted  
region shows the spiked whole blood standards used for quantitation 
(www. biospacelab. com).
The advantages of this technique are that it is quantitative through the use of 
radio-labelled standards and produces images with good spatial resolution (50- 
100 pm). However as previously mentioned the disadvantages of this technique 
are that it only monitors the distribution of the radio-labelled material; it cannot 
distinguish between parent compound and its associated metabolites, which
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complicates the interpretation of the images. Also the technique is time 
consuming as images can take several days or up to a week to develop as 
opposed to MALDI images taking a few hours to produce. It is also a costly 
technique requiring expensive equipment and the synthesis of the radiolabelled 
drug (Solon et a!., 2009).
4.1.1.2. Tissue homogenisation followed by LC-MS/MS
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) is a 
technique routinely employed in the pharmaceutical industry to both identify and 
quantify drugs and related compounds in biological tissues. This method 
requires the entire tissue to be homogenised, followed by sample extraction 
procedures. The ability to monitor the spatial distribution of the parent 
compound and associated metabolites is then lost during this process. The 
technique also assumes that the tissue is homogeneous and does not take into 
account the various compartments of a particular tissue (Castellino et al., 2011, 
Wang et al., 2005).
4.1.2. Quantitation by MALDI-MSI
The advantages of MALDI-MSI are that it is a label free technique, it can 
simultaneously monitor the distribution of parent compound and metabolites 
and produce high spatial resolution images (<30 pm). The technique also 
maintains the spatial orientation of the compound and its metabolites within a 
tissue section and can produce images faster than the QWBA technique. These 
factors may make MALDI-MSI an amenable technique for the quantitation of 
pharmaceuticals in tissue sections.
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However there are several issues that need to be addressed if quantitative 
information is to be generated by MALDI-MSI. These include tissue related ion 
suppression, substance specific ionisation yield and matrix deposition (Stoeckli 
etal.,2007).
Tissue related ion suppression occurs due to the drug being situated in a 
complex environment and as a result there is an ionisation competition between 
the analyte and endogenous species such as lipids (Hamm et al., 2012a, 
Prideaux and Stoeckli 2012).
This phenomenon has been demonstrated by coating an entire whole body rat 
section with a compound solution using a pneumatic sprayer, which was then 
analysed by MALDI-MSI. The resulting image showed differences in ion signal 
intensity of the compound in different organs (Stoeckli et al., 2007).
In order to correct for this (Hamm et al., 2012a) developed a normalisation 
factor called the tissue extinction coefficient (TEC) to take into account the ion 
suppression effect, based on the initial work reported by (Stoeckli et al., 2007). 
This method involves homogenously coating a control tissue section with the 
matrix containing the analyte of interest, the coated tissue section is then 
analysed. Following analysis regions of interest are selected on and off the 
tissue section, the TEC is calculated by determining the average intensity of a 
region on the tissue and dividing it by that of a region off the tissue. A dilution 
series of the analyte of interest is placed next to the dosed tissue, which are 
then coated with the matrix and analysed. The average intensity of the analyte 
of interest in a tissue section is determined and then multiplied by the TEC 
value. Using the dilution series a calibration curve is then produced and used to 
determine the amount of drug in the dosed tissue section.
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This method was used for the quantitation of olanzapine in rat kidney sections 
and propranolol in multiple organs of a whole body section of a mouse by 
(Hamm et al., 2012b). The results showed good correlation to those produced 
by validated techniques such as LC-MS/MS and QWBA.
Signal variation within a sample can also be caused by inhomogeneous matrix 
coverage and crystal formation. This can be solved by careful matrix selection 
and preparation, also by the use of modern matrix deposition devices that are 
capable of providing reproducible and homogeneous matrix deposition.
Another limitation with the quantitative analysis of pharmaceutical compounds 
by MALDI-MSI is isobaric interference from the MALDI matrix and/ or 
endogenous species present in the sample. Such interferences can be 
overcome by careful matrix selection, the use of mass spectrometers with high 
resolving power such as Fourier transform ion cyclotron resonance mass 
spectrometry (FT-ICR-MS) or the use of ion mobility separation (discussed in 
detail in Chapter 1). The use of FT-ICR-MS for the analysis of pharmaceutical 
compounds was reported by (Cornett et al., 2008) for the analysis of olanzapine 
and its two major metabolites within rat liver and kidney tissue sections. The 
use of ion mobility separation in pharmaceutical research was reported by (Trim 
et al., 2009). In this work the utilisation of ion mobility separation allowed the 
differentiation of the anti-cancer drug vinblastine and its metabolites from 
interfering isobaric ions associated with endogenous species, thus increasing 
the confidence in the resulting data.
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4.1.3. Previous examples of quantitation by MALDI-MSI 
MALDI-MSI has always been regarded as a qualitative technique, however 
several methods showing the possibility of obtaining quantitative information 
have been published.
It has been shown that spotting serial dilutions of a compound onto a control 
tissue section can produce a linear calibration curve. The first demonstration of 
this methodology was by (Nilsson et al., 2010). In this work a dilution series of 
the respiratory compound tiotropium was prepared and spotted onto a control 
rat lung tissue section adjacent to a dosed tissue section. Both MS and MS/MS 
imaging was performed on the spiked and dosed tissue sections, after which a 
calibration curve was produced and used to determine the amount of the 
analyte in areas corresponding to low, medium and high intensity regions. The 
results were shown to correlate well with the results obtained from tissue 
homogenization and LC-MS/MS experiments.
A different approach has been reported by (Koeniger et al., 2011) this involved 
the use of a dilution series, created from a range of rat liver samples dosed 
orally with increasing amounts of the drug olanzapine (0-100 mg/kg). Serial 
tissue sections, taken adjacent to those analysed by MALDI-MSI, were then 
homogenised and analysed by LC-MS/MS, the data showed good correlation 
between the two techniques.
Whilst not an example of quantitative mass spectrometry imaging (Becker et al., 
2005) developed a method for the analysis of atomic species by laser ablation 
inductively coupled plasma-mass spectrometry imaging (LA-ICP-MSI). A 
dilution series of different atomic species was mixed with tissue homogenate. 
These were then snap frozen, sectioned and mounted next to tissue sections of 
human brain. This method was then later adapted by (Hamm et al., 2012a) for
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MALDI-MSI and involves the preparation of a dilution series of a drug, which 
was then mixed with tissue homogenate. The spiked homogenate was snap 
frozen, sectioned and mounted next to the dosed tissue section.
Pirman and Yost presented a MSI method for the quantitation of endogenous 
acetyl-L-carnitine in piglet brain tissue sections. In this work a dilution series of 
acetyl-L-carnitine was spotted onto a microscope slide and allowed to dry, after 
which deuterated acetyl-L-carnitine was applied on top of the standards using 
an adapted ink-jet printer. Piglet brain tissue sections were then thaw mounted 
over the calibration standards and internal standard, matrix was then applied 
and the sections analysed.
The calibration standards and internal standard were applied under the tissue to 
mimic the extraction process of the analyte from dosed tissue sections into the 
matrix crystals. MS/MS imaging was then performed with a wide isolation 
window to ensure that both transitions for the analyte and the deuterated 
internal standard were analysed (Pirman and Yost 2011).
This method was used by (Pirman et al., 2013) for the analysis of cocaine in 
human brain tissue sections, the results were reported to be comparable to 
those obtained by LC-MS/MS.
Takai et al., recently monitored the distribution of the dopamine D2 receptor 
selective antagonist raclopride, in whole body mice sections following an 
intravenous administration. Quantitation of raclopride in multiple organs by 
MALDI-MS/MS imaging was performed by correlating the response from each 
organ and comparing this with the tissue concentrations determined by LC- 
MS/MS. The MALDI-MS/MS images were normalised with a product ion of the 
matrix DHB, which was used as an internal standard.
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It has previously been shown by (Koeniger et al., 2010) that there was a linear 
relationship between the amount of the drug olanzapine in a single rat liver 
tissue section analysed by LC-MS/MS and the MSI response in an adjacent 
tissue section. The MALDI-MS/MS images showing the distribution of raclopride 
were compared with WBA results showing the distribution of 3H-raclopride 
(Takai et al., 2012).
4.1.4. Quantitative MSI software
The increasing interest in this field has prompted the creation of quantitative 
mass spectrometry imaging software such as the Quantinetix™ software from 
ImaBiotech (www.imabiotech.com).
Quantitative MSI software called “MALDI tools” has been developed recently by 
Uppsala University (Sweden) and is freely available from www.maldi-msi.org. 
The use of this software was reported by (Kallback et al., 2012) for the 
quantification of the drugs imipramine and tiotropium in rat brain and lung tissue 
sections and the quantification of the endogenous neuropeptide substance P in 
rat brain tissue sections.
4.1.5. Aims and Objectives
The work reported here will evaluate and compare the current methods of 
quantification for MALDI-MS imaging. Also presented is a novel method for the 
preparation of standards for use in the quantification of drugs in tissue sections 
by MALDI-MSI. The standards will be prepared in the form of a homogenate 
standard array.
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4.2. Methods
4.2.1. Information
All animal studies were ethically reviewed and carried out in accordance with 
Animals (Scientific Procedures) Act 1986 and the GSK Policy on the Care, 
Welfare and Treatment of Laboratory Animals.
4.2.2. Materials
The reagents alpha-cyano-4-hydroxycinnamic acid (CHCA), gelatin type B, 
ipratropium bromide monohydrate, fenoterol hydrobromide and trifluoroacetic 
acid (TFA) were purchased from Sigma Aldrich® (Gillingham, Dorset, UK). 
Methanol (MeOH) were purchased from Fisher Scientific (Loughborough, 
Leicestershire, UK), ipratropium bromide and tiotropium bromide were kindly 
provided by GlaxoSmithKline (Stevenage, UK).
4.2.3. Matrix deposition
Samples were coated with either CHCA (7mg/ml in 70:30 MeOH: H2O with 
0.2% TFA) using the ImagePrep matrix application device (Bruker Daltonics, 
Bremen, Germany) or CHCA containing 1 ng/pl of ipratropium as an internal 
standard.
A 5 mg/ml solution of CHCA in 70:30 MeOH: H2O with 0.2% TFA was used for 
samples sprayed on the Suncollect™ automated pneumatic sprayer (Sunchrom, 
Friedrichsdorf, Germany) in a series of layers. The matrix application was 
performed in a series of layers, the initial seeding layer was performed at 2 
pl/minute and subsequent layers were performed at 3 pl/minute.
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4.2.4. Sample preparation
4.2.4.1. On-tissue standard preparation
Control rat lung tissue was laid out on aluminium foil and frozen at -80°C. The 
frozen lung tissue was sectioned using a Leica CM3050 cryostat (Leica 
Microsystems, Wetzlar, Germany) to produce 10 pm thick sections. The cut 
sections were thaw-mounted onto indium tin oxide coated glass slides (Bruker 
Daltonics, Bremen, Germany).
Standards were prepared from a tiotropium stock solution (1 mg/ml adjusted to 
free base form) to give the following standards 1 ng/pl-10 pg/pl in 50:50 
methanol: water. Then 0.5 pi of each standard was spotted onto a control rat 
lung tissue section.
4.2.4.2. Homogenate standard preparation
During the preparation of the lung tissue sections (see 4.2.4.1) five consecutive 
tissue sections were taken and placed into an eppendorf tube and stored at - 
80°C until required.
In order to account for tissue related ion suppression, the volume of each tissue 
section collected was calculated and this volume was used to add to the 
standards. The volume of each tissue section was approximately 17 pm3. This 
was calculated using the Flexlmaging software (Bruker Daltonics) and thus 17 
pi of water was added for each tissue section. To prepare a control rat lung 
tissue homogenate 85 pi of water ( 5x17  pi) was added to five tissue sections. 
The tissue sections and water were sonicated in an eppendorf tube for 
approximately 30 minutes.
To prepare standards of ipratropium, the stock solution (1 mg/ml in water 
adjusted to free base form) was diluted in water to generate the following
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standard solutions 100, 50, 20, 10, 5, 2, 1, 0.5, 0.2 and 0.1 ng/pl. 85 pi of these 
standards was added to the five tissue sections and vortex mixed followed by 
sonication for approximately 30 minutes. 1 pi of each homogenate standard was 
spotted onto a conductive glass slide in triplicate.
4.2.4.3. Homogenate standard section preparation
The lung tissue sections were prepared as described earlier in 4.2.4.1. The 
volume of each tissue section was determined to be approximately 14.6 pm3 
thus, 14.6 pi of water was added for every tissue section. Based upon the 
above measurement 73 pi of water was added to five tissue sections. The 
tissue sections and water were sonicated in an eppendorf tube for 
approximately 30 minutes.
From a stock solution of ipratropium (1 mg/ml in water adjusted to free base 
form) the following standards 100, 50, 20, 10, 5, 2, 1, 0.5, 0.2 and 0.1 ng/pl 
were prepared. 73 pi of these standards were added to the five sections of 
tissue vortex mixed and sonicated for approximately 30 minutes.
In order to prepare the homogenate for freezing 50 pi of a 1 % solution of 
carboxymethyl cellulose was drawn up into a 200 pi (yellow) pipette tip, after 
which the pipette tip was placed into dry ice to freeze the CMC in the pipette tip 
thereby creating a plug. 60 pi of the homogenate was dispensed into the top of 
the pipette tip as shown in Figure 4.2A and frozen in dry ice to freeze. Once 
frozen the bottom of the pipette was discarded and the frozen homogenate 
standard removed from the pipette tip.
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Homogenate dispensed into 
pippette tip
200 pl(yeNow) pipette tip
Mixed tissue homogenate and
Frozen 
1 % carboxymethyloelulos<
Figure 4.2: A) Diagram showing the production of the frozen homogenate 
standards for sectioning using pipette tips as a mold and B) an optical image 
showing a frozen homogenate standard mounted to a cryostat stage.
The frozen homogenate standard was then mounted onto a cryostat stage 
vertically using a 1% solution of carboxymethylcellulose as shown in Figure 
4.2B. The frozen homogenate standards were sectioned using a Leica CM3050 
cryostat (Leica Microsystems, Wetzlar, Germany) to produce 12 pm thick 
sections (12 pm thick sections were found to be manipulated easier). The cut 
sections were thaw-mounted onto indium tin oxide coated glass slides (Bruker 
Daltonics, Bremen, Germany) in triplicate.
4.2.4.4. Homogenate standard array preparation.
Standards of tiotropium bromide were prepared from a 1 mg/ml stock solution in
water adjusted to free base, to give the following standards 100, 50, 20, 10, 5,
2, 1, 0.5, 0.2 and 0.1 ng/pl in water. Control rat lung tissue was snap frozen in
liquid nitrogen cooled isopentane and sectioned using a Leica CM3050 cryostat
(Leica Microsystems, Wetzlar, Germany) to produce 10 pm thick sections. Five
tissue sections were placed in an eppendorf tube, the volume of tissue per
tissue section was approximately 28.5 pm3 (2.85 pm2 x 10 pm) therefore 28.5 pi
of water was added for every tissue section. In order to prepare the
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homogenate standards 142.5 pi (28.5pl x 5 tissue sections) of the standards 
was added to the contents of the eppendorf tubes, the contents of the 
eppendorf tube was vortex mixed and sonicated for approximately 30 minutes. 
The homogenate standards were embedded in pre-frozen gelatin (100 mg/ml 
aqueous), holes were drilled into the frozen gelatin using a RotaCraft RC12VS 
mini rotary tool kit (SHESTO Limited, Willesden, London) fitted with a 3 mm 
diameter drill bit, the holes were then filled with tiotropium homogenate 
standards using a 1ml glass syringe to produce the homogenate standard array 
as shown below in Figure 4.3.
10 ng/pl 20 ng/pl 100 ng/pl
0.2ng/|jl
Figure 4.3: Optical image showing the tiotropium homogenate standards (100 - 
0.1 ng/pl) embedded in frozen the gelatin.
The embedded array of homogenate standards was sectioned at a -20°C using 
a Leica Cryostat (Leica, Wetzlar, Germany) to produce 12 pm thick sections, 
which were thaw mounted onto glass slides.
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The same sample preparation was used to prepare a second homogenate 
standard array using fenoterol standards prepared from a 1 mg/ml stock 
solution in water, to give the following standards 1000, 500, 250, 125, 62.5,
31.2, 15.6, 7.8, 3.9, 1.9 and 0 ng/pl in water.
4.2.5. Instrumentation
4.2.5.1. MALDI-LIFT-MS/MS imaging
Analyses were either performed on an Ultraflex III or UltrafleXtreme MALDI- 
TOF/TOF mass spectrometer (Bruker Daltonics) equipped with smart beam 
laser technology. The digital image of the sections was imported into 
Flexlmaging software (Bruker Daltonics), and through the software the 
instrument was taught the dimensions of the sections.
The instrument was operated in LIFT MS/MS positive mode configuration with a 
potential of 19.14kV for the Ultraflex III instrument or 19.10kV for the
UltrafleXtreme instrument. Data was acquired at a spatial resolution of 200 pm,
with typical laser spot diameters of 75-80 pm. LIFT MS/MS data was acquired in
the mass range between 100 and 500 Da. The acquisition method was 
calibrated using a peptide calibration mixture (Bruker Daltonics) before the start 
of the experiment. MS/MS data was automatically acquired using the 
Flexlmaging software from a total of 200 spectra acquired at each spot position 
using the proprietary random walk mode in four 50-shot increments at a laser 
frequency of 100Hz for the Ultraflex III instrument or 1000Hz for the
UltrafleXtreme instrument (Marshall et a l, 2010).
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4.2.5.2. MALDI-MS and MS/MS imaging
Mass spectra and images were acquired in positive ion mode on an Applied 
Biosystems/MDS Sciex hybrid quadrapole time-of-flight mass spectrometer (Q- 
Star Pulsar-/) with an orthogonal MALDI ion source (Applied Biosystems, Foster 
City, California, USA) and a high repetition Neodymium-doped yttrium vanadate 
(Nd: Y V04) laser (5 KHz) (Elforlight Ltd, Daventry, Northamptonshire, UK). 
Image acquisition was performed at a spatial resolution of 150 pm x 150 pm in 
“Raster Image” mode; images were generated using the freely available 
Novartis Biomap 3.7.5.5 software (www.maldi-msi.org).
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4.3. Results and Discussion
4.3.1. On-tissue standards
The first method evaluated is based upon that proposed by (Nilsson et al., 
2010) and involves the spotting of a dilution series of a compound onto a control 
tissue section.
Here are shown the MALDI-LIFT MS/MS images obtained for a dilution series of 
tiotropium bromide spotted onto a rat lung tissue section acquired on the 
UltrafleXtreme instrument (Figure 4.4). The tiotropium spotted tissue section 
was sprayed with matrix containing ipratropium bromide as an internal standard.
Figure 4.4: MALDt-MS/MS images showing A) the distribution of the product 
ion at m/z 152, derived from the precursor ion of tiotropium at m/z 392 within the 
deposited standards and B) the distribution of the product ion at m/z 166, 
derived from the precursor ion of the internal standard Ipratropium at m/z 332 
within the deposited standards.
The MALDI-LIFT MS/MS images displayed in Figures 4.4A shows the 
distribution of the product ion at m/z 152, which is derived from the precursor 
ion at m/z 392 to be within the spiked areas of the tissue section. The image 
shows that the approximate limit of detection of tiotropium as 20 pg/pl, (which 
agrees with the results obtained in the initial feasibility study, Chapter 3). The 
insert shows an expanded view of the sampling points for one of the standards.
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Figure 4.4B shows the distribution of the product ion at m/z 166, which is 
derived from the precursor ion at m/z 332 of the internal standard ipratropium to 
be within the spiked areas of the tissue section. The image shows the presence 
of the internal standard in all of the compound spotted areas of the tissue 
section and the signal intensity is consistent showing no areas of ion 
suppression on this sample.
The filter data (pixel co-ordinates and the intensity of a selected mass) from the 
images presented in Figure 4.4 were exported from the Flexlmaging software 
(Bruker Daltonics) in the form of a text file, and opened in an Microsoft excel 
spreadsheet to be processed and to construct the calibration curve. The 
average intensity of each region was determined and plotted against the 
standards respective concentration (see Figure 4.5).
y = 7,5825x- 0.1981 
R* = 0,8226
Concentration (ng/pL)
Figure 4.5: Calibration curve showing the exported filter data from the MALDI- 
LIFT MS/MS image showing the tiotropium standards spotted onto the control 
tissue section.
157
The calibration curve displayed above in Figure 4.5 shows the filter data from 
the image shown in Figure 4.4A, which shows the distribution of the product ion 
of tiotropium at m/z 152. The graph shows a linear response (R2=0.8226) and 
that values for the 0.8 and 0.4 ng/pl do not fit the line. To determine if these 
points are outliers, the Grubbs statistical test for outliers was performed. The Q 
values for the 0.4 ng/pl and 0.8 ng/pl points were calculated at 0.9144 and 
0.6187 respectively. As these values are above the tabulated Q value (0.552) 
for the number of points in the graph with a 95% confidence, these points 
cannot be classed as statistical outliers and therefore cannot be removed.
The graph shown below in Figure 4.6, is the filter data from the image showing 
the distribution of the product ion at m/z 152 (Figure 4.4A) following 
normalisation with the filter data from the product ion of the internal standard at 
m/z 166 (Figure 4.4B).
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Figure 4.6: Calibration curve showing the exported filter data from the MALDI- 
LIFT MS/MS image showing the tiotropium standards spotted onto the control 
tissue section following normalisation against the internal standard.
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The graph shown in Figure 4.6 shows the filter data from the image shown in 
Figure 4.4A which shows the distribution of tiotropium (m/z 152) following 
normalisation against the filter data from the image shown in Figure 4.4B which 
shows the distribution of the internal standard Ipratropium, the graph shows a 
linear response (R2=0.9944) and showed that the value for the 0.8 ng/pl did not 
fit the line. Again, to ascertain if this point is an outlier, the Grubbs statistical test 
for outliers was performed. The calculated Q value for the 0.8 ng/pl point was 
0.5369, because this value is below the tabulated Q value (0.552) for the 
number of points in the graph with a 95% confidence this point can be classed 
as a statistical outlier and removed.
The graph in Figure 4.6 shows a significant improvement as a result of the 
internal standard over that shown in Figure 4.5 based upon the correlation 
coefficient value. Therefore for future experiments involving Ipratropium shall be 
used as an internal standard, which shall be incorporated into the matrix as 
shown here.
Whilst this method can determine the approximate amount of compound in 
various areas of the sample, the calibration curve may not accurately represent 
the response obtained from the sample (Koeniger et a i, 2011). This could be 
possibly due to the difference in the matrix extraction efficiency of compound 
from the sample in comparison to the spiked tissue. Also uncontrolled 
deposition of standards onto the control tissue section can produce misleading 
results as all standards will not be uniform due to spreading on the tissues 
surface (Pirman etal., 2013).
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4.3.2. Homogenate standards
The second experiment involved mixing the dilution series of ipratropium 
bromide with tissue homogenate, which is used to mimic the behavior of the 
compound in a complex environment. The MALDI-LIFT MS/MS image of the 
mixed ipratropium bromide homogenate standards acquired on the Ultraflex III 
instrument is shown below in Figure 4.7, the mixed homogenate standards were 
analysed in triplicate.
Figure 4.7: MALDI-LIFT MS/MS image showing the distribution of the product 
ion at m/z 166, derived from the precursor ion of ipratropium at m/z 332 within 
the mixed homogenate standards (200 pm spatial resolution).
The MALDI-LIFT MS/MS image displayed above in Figures 4.7 shows the 
distribution of the product ion at m/z 166, which is derived from the precursor 
ion at m/z 332 in the homogenate standards on the glass slide. The images also 
show that visually the limit of detection is approximately 0.5 ng/pl.
The calibration curve was constructed from the filter data as described in 4.3.2. 
The average intensity of each region was calculated and plotted against the 
standards respective concentration, see Figure 4.8.
160
16
y = 0,1399x + 0.2264 
R* = 0,989
0 4010 20 30 50 60 70 80 10090
Concentration (ng/pl)
Figure 4.8: Graph showing the exported filter data from the MALDI-LIFT- 
MS/MS image showing the distribution of ipratropium within the mixed 
homogenate standards.
The calibration curve shown in Figure 4.8 shows a linear response (R2=0.9889) 
ranging from 0.1-100 ng/pl (three orders of magnitude).
The advantages of this homogenate standard method are that it accounts to 
tissue related ion suppression due to the homogenate and there is more control 
over the deposition of these standards, because the homogenate standards 
were prepared in water with no solvent.
However the disadvantages of this method are it is tissue specific and the 
deposits may not be fully applicable to the dosed tissue section, and as for the 
previous method the matrix extraction efficiency may not be the same.
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4.3.3. Homogenate standard sections
The third method investigated involved the preparation of homogenate 
standards like the previous method, however in this case the homogenate 
standards were snap frozen, sectioned and thaw mounted onto a glass slide. 
This method was demonstrated in the work reported by (Becker et al., 2005). 
The MALDI-LIFT MS/MS image of the homogenate standard sections acquired 
on the UltrafleXtreme instrument are shown below in Figure 4.9, the 
homogenate standard sections were analysed in triplicate.
Figure 4.9: MALDI-LIFT MS/MS image showing the distribution of the product 
ion at m/z 166, derived from the precursor ion of ipratropium at m/z 332 within 
the homogenate standard sections (200 pm spatial resolution).
The MALDI-LIFT MS/MS image displayed in Figures 4.9 shows the distribution 
of the product ion at m/z 166, which is derived from the precursor ion at m/z 332 
to be within the homogenate standard sections. The image shows the 
distribution of ipratropium (m/z 166) within the homogenate standard sections, 
the image shows that visually the limit of detection is approximately 0.2 ng/pl. 
The filter data from the above image was exported from Flexlmaging software 
(Bruker Daltonics) in the form of a text file, which was opened in an excel 
spreadsheet to be processed. The average intensity of each region was
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determined and plotted against the standards respective concentration, the 
results of which are shown in Figure 4.10.
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Figure 4.10: Calibration curve showing the exported filter data from the MALDI- 
LIFT MS/MS image showing the three replicates of ipratropium homogenate 
standard sections.
The calibration curve displayed in Figure 4.10 shows the filter data from the 
image shown in Figure 4.9 which shows the distribution of ipratropium (m/z 
166). The calibration curve shows a linear response for the homogenate 
standard sections (R2=0.9766) ranging from 0.1 -  20 ng/pl (over two orders of 
magnitude). The results from the 50 and 100 ng/pl were excluded from the plot 
as they caused the graph to plateau, this could be due to the dynamic range of 
the instrument.
The advantages of this method are the standards are matrix matched, also the 
standard sections are comparable to the dosed tissue sections because like 
them the compound is within the standard sections and are the same section 
thickness, and thus should have similar extraction efficiencies. However the
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major disadvantage of this technique is that it is time consuming to prepare and 
section all of the individual standards.
4.3.4. Homogenate standard array
The main disadvantage of the homogenate standard section approach was the 
lengthy procedure, to overcome this the homogenate standard array was 
developed. This method consists of a range of homogenate standards 
embedded in a frozen gelatin block that can be sectioned and placed next to a 
dosed tissue section.
The MALDI-MS/MS images of the tiotropium bromide homogenate standard 
array (100-0.1 ng/pl) acquired on the QSTAR instrument are shown below in 
Figure 4.11. I 227 1 . 
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Figure 4.11: MALDI-MS/MS image showing the distribution of the product ions 
at m/z 152 (left) and 170 (right), derived from the precursor ion of tiotropium at 
m/z 392 (150 pm spatial resolution).
The MALDI-MS/MS images displayed in Figure 4.11 shows the distribution of
the two product ions at m/z 152 and 170 respectively, derived from the
precursor ion of tiotropium at m/z 392 to be within the homogenate standard
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array. The images show a decreasing response with respect to the 
concentration of the standards in the array, also the distribution of the product 
ions at m/z 152 and 170 appears to be homogenous within each standard.
Utilising the region of interest tool of the BioMap 3.7.5.5 software, the average 
intensity of each standard was determined and plotted against the standards
respective concentration, the results of which are shown in Figure 4.12.
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Figure 4.12: Graph produced from region of interest analysis on the distribution 
of the product ion at m/z 172, derived from the precursor ion of tiotropium at m/z 
392.
The calibration curve shown in Figure 4.12 shows a linear response 
(R2=0.9714) ranging from 0.1-10 ng/pl (two orders of magnitude). The results 
from the 20-100 ng/pl were again excluded since they caused the graph to 
plateau.
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To demonstrate the application of the homogenate standard array method of 
quantification by MALDI-MSI to different pharmaceutical compounds a second 
homogenate standard array was made using the long acting (32-adrenoreceptor 
agonist fenoterol, which is not as easily ionised by MALDI in comparison to the 
quaternary ammonium compounds analysed previously.
The MALDI-MS/MS image of the fenoterol homogenate standard array (0-1000 
ng/pl) acquired on the QSTAR instrument is shown below in Figure 4.13.I 2623.1 
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Figure 4.13: MALDI-MS/MS image showing the distribution of the product ions 
at m/z 107 (left) and 135 (right), derived from the precursor ion of fenoterol at 
m/z 303 (150 pm spatial resolution).
The MALDI-MS/MS images shown in Figure 4.13 shows the distribution of two
of the most abundant product ions at m/z 107 and 135 respectively, derived
from the precursor ion of fenoterol at m/z 303 to be within the homogenate
standard array. The images show a decreasing response with respect to the
concentration of the standards in the array, also the distribution of the product
ions at m/z 107 and 135 appears to be homogenous within each standard.
The calibration curve was constructed using the region of interest data as
described in previously, the results of which are shown in Figure 4.14.
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Figure 4.14: Graph produced from region of interest analysis on the distribution 
of the product ion at m/z 107, derived from the precursor ion of fenoterol at m/z 
303.
The calibration curve shown in Figure 4.14 shows a linear response 
(R2=0.9797) ranging from 31-1000 ng/pl.
The advantages of the homogenate standard array method are the standards 
are comparable to the dosed tissue sections because like them the compound 
is within the standard sections and are the same section thickness, thus will 
have similar extraction efficiencies. Another advantage of this approach is that 
all of the homogenate standards are embedded in a block of frozen gelatin. One 
section contains all the standards necessary for quantitation which can be 
placed next to the dosed tissue section and analysed at the same time.
Another envisaged use of the homogenate standard array could be to do quality 
assurance checks on instruments, to ensure they are operating at optimal 
performance from day-to-day.
167
4.4. Conclusion
The purpose of this study was to evaluate the use of the current reported 
methods for the generation of quantitative information from mass spectrometry 
images.
There are currently three methods reported for generating quantitative 
information from mass spectrometry images, the first method involves the 
spotting of a dilution series of a drug onto control tissue sections to generate a 
calibration curve, this is then used to determine the amount of the analyte of 
interest in different areas of the dosed tissue section as recently described by 
(Nilsson et a/., 2010). Whilst this method allows for the approximate amount of a 
particular compound to be assigned to a specific region on a treated tissue 
section, the calibration cannot be accurately assigned based upon the 
difference in extraction efficiencies between standards and sample. The second 
method involved the preparation of “matrix-matched” homogenate standard 
sections based upon the work reported by (Becker et a/., 2005). The advantage 
of this technique is homogenate standard sections are the same thickness as 
the treated tissue section. The standards are located within the section and 
mimic a dosed compound present in a tissue sample, the extraction efficiencies 
should be similar. Finally this work has also looked at homogenate standards 
spotted onto a glass slide.
This study has led to the development of a novel quantitation method in the 
form of a homogenate standard array, which consists of homogenate standards 
embedded in a block of frozen gelatin. Sections of the homogenate standard 
array has the advantage that it can be placed next to a dosed tissue section and 
analysed at the same time and under the same conditions as the dosed tissue
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section and contains all the standards necessary for making an estimate of the 
drug levels in the tissue.
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Chapter 5
Development of methodology for monitoring the three-dimensional distribution 
of endogenous species in the lungs by MALDI-MSI
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5.1. Introduction
5.1.1. Traditional 3D imaging techniques
Current well-established bioimaging techniques include positron emission 
tomography (PET), computed tomography (CT) and magnetic resonance 
imaging (MRI). These techniques give anatomical information by monitoring the 
distribution of water or the distribution of a labeled compound. PET is a labeled 
technique which utilises radiotracers which are isotopes that have a short half- 
life i.e. Carbon-11 or Fluorine-18, which are often incorporated into glucose or 
compounds such as Raclopride. MRI and CT are targeted techniques and can 
recover the anatomy of the body or a specific organ by tracing water or other 
fluid molecules.
However these techniques do not have the ability to monitor the distribution of 
unlabelled drugs and metabolites or proteins (Crecelius et al., 2005, Trede et 
a/., 2012). MALDI-MSI has been extensively used to monitor the distribution of 
pharmaceutical compounds, lipids, peptides and proteins in tissue sections. 
Expanding this technique with the addition of a third dimension enables a 
detailed, volumetric visualization of these analytes in an entire organ (Crecelius 
et al., 2005, Ye et al., 2011).
5.1.2. Current approaches to 3D-MSI
There are currently two approaches used for three-dimensional mass 
spectrometry imaging (3D-MSI), depth profiling and serial-sectioning. In the 
depth profiling approach, ablation of the sample surface is performed exposing 
lower layers for analysis. This approach has been reported using SIMS and 
LAESI (Nemes et al., 2009, Fletcher et al., 2011). For the serial-sectioning 
approach, the sample is cut into serial sections, each section is imaged and the
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images then combined into a 3D model. This approach has been reported using 
both MALDI and DESI (Crecelius et al., 2005, Ye et al., 2011, Xiong et al., 
2012).
5.1.3. Previous Examples
5.1.3.1. 3D MALDI-MS Imaging
The first report of the construction of 3D MALDI-MS images came from 
(Crecelius et al., 2005). In this work a three-dimensional model of the 
distribution of the myelin basic protein (MBP) in the corpus callosum of a mouse 
brain was constructed. The mouse brain was sectioned into a total of 264 tissue 
sections, from these sections 10 were selected at equal intervals and analysed 
by MALDI-MSI. The MALDI-MS images were then co-registered with optical and 
histological images, as well as anatomical references. The results of this 
reconstruction are shown below in Figure 5.1.
Figure 5.1: 3D MALDI-MS image of myelin basic protein in the corpus callosum 
of a mouse brain. The yellow volume corresponds to the outline of the entire 
corpus callosum from 264 optical images (Crecelius et al., 2005).
A detailed step-by-step procedure for the production of 3D volume 
reconstructions of MALDI-MS data was reported by (Andersson et al., 2008).
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Here the distribution of peptides and proteins were localized in the substansia 
nigra and the interpedunclar nucleus of the rat brain. Figure 5.2 shows the co­
localisation of PEP-19 and an unidentified protein from four different angles.
Figure 5.2: 3D MALDI-MS images of the substantia nigra and interperduncular 
nucleus. The images show the distribution of PEP-19 (green) which is localised 
in both regions and a protein with m/z 7416 (red) localised in the substansia 
nigra (Seely and Caprioli 2012).
Later (Sinha et al., 2008) demonstrated the integration of magnetic resonance 
imaging (MRI) with MALDI-MSI of a whole mouse head into the same three- 
dimensional model. In this work high resolution MRI of a tumor-laden mouse 
brain was performed, after which the animals were sacrificed and serial sections 
were collected and analysed by MALDI-MSI, the data was then co-registered 
with the MRI data showing the distribution of proteins in relation to anatomical 
features of the brain as shown in Figure 5.3.
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Figure 5.3: Co-registered MALDI-MS images and MRI of a whole mouse head. 
The MALDI-MSI images (colour scale) of A) the astrocytic phosphoprotein 
(Pea 15) and B) the fatty acid binding protein 5 (Fabp5) are co-registered with 
the MRI data (grey scale) and an optical image (Sinha et a!., 2008).
The distribution of peptides and lipids in the brain of a crab, Cancer borealis 
was demonstrated by (Chen et al., 2009). The brain was embedded in gelatin 
and sectioned. Seven sections were collected with a spacing of 132 pm. These 
sections were analysed and the three-dimensional distribution of brain 
components such as the neuropeptide C. borealis tachykinin-related peptide 
(CabTRP) 1a and the lipid phosphatidylcholine (PC) 38:6 were generated. 
Figure 5.4 shows the 3D distribution of a lipid and a peptide in a crab brain.
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Figure 5.4: 3D reconstruction of MALDI-MS images of (A) the neuropeptide C. 
borealis tachykinin-related peptide (CabTRP 1a) and (B) lipid PC 38:6 acquired 
from the brain of a crab (Chen et al., 2009).
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The use of fiducial or registration markers for 3D image alignment and 
reconstruction was demonstrated by (Chughtai et al., 2012). The use of a 
fiducial markers comprised of cresyl violet and Ponceau S, was found to be 
compatable with other imaging modalities such as bright field micropscopy, 
fluorescence, and histological imaging. The use of the fiducial markers enabled 
data obtained using these techniques to be incorporated into the same 3D 
images as the MSI data, which is shown below in Figure 5.5.
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Figure 5.5: 3D images showing the co-registration of from optical imaging, H&E 
imaging, and MSI based on the position of the fiducial markers. (A) co­
registration of MSI data (gray), optical imaging data of the tumor boundary 
(yellow mesh) and the hypoxic region (red). (B) co-registration of MSI data of 
actin (grey) and tdTomato (red) and H&E imaging data (yellow mesh) 
(Chughtai et al., 2012).
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5.1.3.2. 3D LAESI-MS Imaging
The first example of 3D-MS imaging under atmospheric pressure (AP) 
conditions using LAESI-MS imaging was reported by (Nemes et al., 2009). In 
this work the distribution of various metabolites such as kaempferol/luteolin, 
chlorophyll a, acacetin and kaempferol (diacetyl coumarylrhamnoside) were 
monitored in the leaves of the zebra plant (Aphelandra squarrosa). The 3D 
distribution of metabolites was achieved using both lateral imaging and depth
profiling. The results are displayed below in Figure 5.6.
Figure 5.6: Optical images of Aphelandra squarrosa leaves (A) before and (B) 
after analysis. (C) 3D LAESI-MS images showing the distribution of 
kaempferol/luteolin (yellow/orange scale) which follow the variegation pattern 
and chlorophyll (blue scale) accumulated in the mesophyll layers (Nemes et al., 
2009).
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5.1.3.3. 3D DESI-MS Imaging
The first 3D molecular reconstruction of a mouse brain using DESI-MS imaging 
was reported by (Eberlin et al., 2010). The distribution of the two lipids (PS and 
ST) was demonstrated in serial sections of the mouse brain. The distribution of 
phosphatidylserine (PS) 18:/22:6 and sulfatide (ST) 24:1 were localised in the 
grey matter and white matter respectively. The distribution of these lipids was 
overlaid to construct a 3D model, which allowed a complete view of 
substructures such as the corpus callosum and anterior commissure. As shown 
in Figure 5.7.
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Figure 5.7: 3D DESI-MS images o f the mouse brain showing (A) PS 18:0/22:6 
in green, (B) ST 24:1 in red and (C) PI 18:0/22:6 in blue. The same views are 
shown for the transparent overlaid distributions o f the lipids (D) PS 18:0/22:6 
and ST 24:1 and (E) PS 18:0/22:6 and PI 18:0/22:6 (Eberlin et al., 2010).
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5.1.3.4. 3D TOF-SIMS Imaging
The application of SIMS for 3D imaging of single cells has recently been 
demonstrated by Fletcher et al., in 2011. 3D-MS imaging of HeLa-M cells 
prepared either by formalin fixation freeze-drying (Figure 5.8A) or a hydrated 
freeze fracture (Figure 5.8B) method was performed. The distribution of adenine 
at m/z 136 was localised in the nucleus and phosphocholine at m/z 184 was 
localised in the cell membrane.
Figure 5.8: 3D visualisation o f SIMS depth profiling o f HeLa-M cells prepared  
by A) the formalin fixation freeze-drying and B) the hydrated freeze fracture 
(right). The images show phosphocholine at m/z 184 (green) localised in the cell 
membrane and adenenine at m/z 136 or guanine at m/z 156 localised in the 
nucleus (Fletcher et al., 2011).
The first 3D molecular reconstruction of a rat heart by SIMS imaging was 
recently reported by (Fornai et al., 2012). A rat heart was serially sectioned 
resulting in 40 tissue sections, the sections were then analysed using metal 
assisted-secondary ion mass spectrometry (MetA-SIMS). The 3D images 
showed the distribution of sodium at m/z 23 was localised in the atria, 
potassium at m/z 39 was localised in the ventricles and an endogenous species 
at m/z 145 was localised in the pulmonary artery, right atrium, and
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atrioventricular valve. The reconstruction of the heart is displayed from different 
angles below in Figure 5.9.
Figure 5.9: 3D SIMS-MS images o f a rat heart showing the distribution o f an 
endogenous species at m/z 145 (red), sodium at m/z 23 (green) and potassium  
at m/z 39 (blue) from different angles (Fornai et al., 2012).
5.1.4. Aims and Objectives
The aim of this experiment is to develop methodology to monitor the three- 
dimensional distribution of endogenous species throughout the lungs using 
MALDI-MSI. Serial sections were obtained at equal intervals through the control 
mouse lung tissue and imaged individually; homogenate registration markers 
were incorporated in order to aid the final 3D image construction.
Using Image J, a freely available software the images were stacked together to 
generate the 3D distribution of a particular endogenous species throughout the 
lungs to be displayed, the Volume Explorer software was also used to produced 
3D MALDI-MSI images.
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5.2. Methods
5.2.1. Information
All animal studies were ethically reviewed and carried out in accordance with 
Animals (Scientific Procedures) Act 1986 and the GSK Policy on the Care, 
Welfare and Treatment of Laboratory Animals.
5.2.2. Materials
The reagents alpha-cyano-4-hydroxycinnamic acid (CHCA), gelatin type B and 
trifluoroacetic acid (TFA) were purchased from Sigma Aldrich® (Gillingham, 
Dorset, UK). Methanol (MeOH) was purchased from Fisher Scientific 
(Loughborough, Leicestershire, UK).
5.2.3. Tissue Preparation
A control mouse lung tissue was embedded in gelatin (100 mg/ml aqueous) as 
shown in Figure 5.10 and placed into a -80°C freezer. Holes were drilled into 
the frozen gelatin using a RotaCraft RC12VS mini rotary tool kit (SHESTO 
Limited, Willesden, London) fitted with a 3 mm diameter drill bit. The holes were 
then filled with control rat lung homogenate, these act as registration markers 
for later image reconstruction. The embedded tissue was then sectioned at a 
temperature of -20°C using a Leica Cryostat (Leica, Wetzlar, Germany) to 
obtain 12 pm sections at 120 pm intervals, which were thaw mounted onto 
glass slides.
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Figure 5.10: Optical images showing the control mouse lung tissue embedded 
in gelatin prior to freezing.
5.2.4. Matrix Application
The matrix solution 5 mg/ml CHCA in 70:30 MeOH: H2 O with 0.2% TFA was 
applied using the Suncollect™ automated pneumatic sprayer (Sunchrom, 
Friedrichsdorf, Germany) in a series of layers. The initial seeding layer was 
performed at 2 pl/minute and subsequent layers were performed at 3 pl/minute.
5.2.5. Instrumentation
Mass spectra and images were acquired in positive ion mode on an Applied 
Biosystems/MDS Sciex hybrid quadrupole time-of-flight mass spectrometer (Q- 
Star Pulsar-/) with an orthogonal MALDI ion source (Applied Biosystems, Foster 
City, California, USA) and a high repetition Neodymium-doped yttrium vanadate 
(Nd: YVO4 ) laser (5 KHz) (Elforlight Ltd, Daventry, Northamptonshire, UK). 
Image acquisition was performed at a spatial resolution of 150 pm x 150 pm in 
“Raster Image” mode; images were generated using the freely available 
Novartis Biomap 3.7.5.5 software (www.maldi-msi.org).
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5.2.6. Data Processing
Images generated in the Biomap 3.7.5.5 software were exported in JPEG 
format and imported into the Image J software (http://rsbweb.nih.gov/ii/). Images 
were orientated and aligned before being integrated as an image stack, which 
was then viewed as a 3D volume using the 3D viewer option.
Mass spectral post-processing was performed on regions of interest in Biomap, 
then converted into text files and imported into mMass software (Strohalm et al., 
2010).
The Datacube Explorer software (www.imzml.org) was used to further process 
the raw data in order to create what are known as datacubes. Spectral binning 
was also performed to reduce the size of the dataset. Then using the Volume 
Explorer software developed at FOM Institute AMOLF (Amsterdam, The 
Netherlands) these datacubes were used to create 3D volumes. Individual 
images were manually aligned with the aid of the registration markers (Klinkert 
and Heeren 2013).
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5.3. Results and Discussion
One of the challenges of 3D MALDI-MS imaging is that it requires the 
preparation of high quality tissue sections. The frozen tissue sample is sliced 
into serial sections, tissue tearing, rolled-up edges and deformations can make 
the correlation of consecutive images difficult (Chughtai and Heeren 2010). 
Gelatin was chosen to embed the control mouse lung tissue because it 
preserves the integrity and morphology of the tissue, and gelatin provides less 
mass spectral interference than optimal cutting temperature (OCT) embedding 
media usually used for cryosectioning (Chen et al., 2009).
The MALDI-MS spectra obtained from the control mouse lung tissue and 
registration markers is shown below in Figure 5.11.
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Figure 5.11: MALDI-MS spectra obtained from the control mouse lung tissue 
(blue spectrum) and the registration markers (red spectrum).
A region of interest was drawn on the control mouse lung tissue and on one of 
the registration markers; the corresponding peak list was exported in text format 
and imported into the mMass software (Strohalm et al., 2010). The mass
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spectra (obtained from the two regions) were displayed in pairs by flipping one 
of the spectra as shown in Figure 5.11. In the case of both regions there is an 
abundance of lipid species such as choline at m/z 104, possible 
lysophosphatidylcholine at m/z 496 and phosphocholine at m/z 184 which is the 
most abundant peak in both regions.
The MALDI-MS images obtained for the distribution of various endogenous 
species in the control mouse lung tissue sections (previously seen in Figure 5.2) 
are displayed below in Figure 5.12.
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Figure 5.12: MALDI-MS images showing the distribution o f various endogenous 
species in the control mouse lung tissue section (150 pm spatial resolution).
The MALDI-MS images displayed above in Figure 5.12 shows the distribution of 
various endogenous species throughout the control mouse lung tissue. Such as 
choline at m/z 104 (Figure 5.6A) which is localised in specific regions of the 
tissue section and phosphocholine at m/z 184 (Figure 5.6D) which is distributed
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throughout the control mouse lung tissue section. Other species possibly 
included a lysophosphatidylcholine at m/z 496 (Figure 5.6G) and 
phosphatidylcholines at m/z 734 and 756 (Figures 5.6K and 5.6L respectively) 
are also widespread throughout the lungs tissue sections. All these selected 
species were observed in each of the homogenate registration markers located 
in the four corners of the images.
In order to confirm the identity of the lipds MS/MS experiments were performed. 
The MALDI-MS/MS images showing the distribution of phosphocholine is 
shown below in Figure 5.13.
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Figure 5.13: MALDI-MS/MS images showing the distribution o f the product ion 
at m/z 124, derived from the precursor ion o f phosphocholine at m/z 184 (150 
pm spatial resolution).
The images displayed above in Figure 5.13 shows the distribution of the product 
ion at m/z 124, derived from the precursor ion of phosphocholine at m/z 184 
(previously shown to be the most abundant endogenous species) to be within 
the control mouse lung tissue in the centre but also in the four registration 
markers located in the four corners.
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The generation of a three-dimensional image was performed by serially 
sectioning the mouse lung tissue with defined and measured spatial intervals (z- 
dimension), a total of 28 sections were collected and analysed by MALDI-MSI. 
The resulting 2D MALDI-MS images of the first sixteen images generated 
showing the distribution of phosphocholine in the control mouse lung tissue are 
presented below in Figure 5.14.
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Figure 5.14: 2D MALDI-MS images showing the distribution of phosphocholine 
at m/z 184 following normalization against the protonated CHCA matrix at m/z 
190, throught the first 16 control mouse lung tissue sections.
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The MALDI-MS images displayed above in Figure 5.14 show the distribution of 
phosphocholine at m/z 184 throughout the first 16 serial tissue sections. The 
distribution was chosen to show the structure of the tissue sections.
The three-dimensional model of the control mouse lungs was constructed using 
the first 16 2D MALDI-MS images. The 3D reconstruction of the distribution of 
phosphocholine at m/z 184 generated using the Image J software is shown 
below in Figure 5.15 and is displayed from different angles.
Figure 5.15: 3D MALDI-MS images produced using Image J software showing 
the distribution of phosphocholine at m/z 184 following normalization against the 
protonated CHCA matrix at m/z 190, throughout the control mouse lung tissue 
from different angles.
The 3D MALDI-MS images showing the distribution of phosphocholine at m/z 
184 (Figure 5.15) is displayed from different angles. The images show that 
phosphocholine is widely distributed and only shows the external structure of 
the control mouse lungs, however the images clearly display trachea and the 
right and left lobes.
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The 2D data generated was also processed using the Volume Explorer 
software, the registration of individual images was performed by manual 
alignment (offset in the x and y directions) with the aid of the four registration 
markers. The 3D reconstruction of the distribution of phosphocholine at m/z 184 
obtained from the 16 2D images, generated using the Volume Explorer software 
is displayed from different angles below in Figure 5.16.
Figure 5.16: 3D MALDI-MS images produced using Volume Explorer software 
showing the distribution of phosphocholine at m/z 184 following normalization 
against the protonated CHCA matrix at m/z 190, throughout the control mouse 
lung tissue from different angles.
The 3D MALDI-MS images displayed above in Figure 5.16 shows the 
distribution of phosphocholine at m/z 184 displayed from different angles. Again 
the images demonstrate that phosphocholine is widely distributed and only 
reveals the external structure of the control mouse lungs, such as the trachea 
and the right and left lobes are displayed.
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The Volume Explorer software is also capable of displaying the distribution of 
up to three masses in the same 3D model, this is demonstrated below in Figure 
5.17.
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Figure 5.17: 3D MALDI-MS images showing the distribution of A) a possible 
phosphatidylcholine at m/z 756.5, B) the heme group of hemoglobin at m/z 
616.2 C) another possible phosphatidylcholine m/z 760, D) an overlay of the 
phosphatidylcholine at m/z 756.5 and the heme group at m/z 616 and E) an 
overlay of all three endogenous species.
The 3D models displayed above in Figure 5.17 show the distribution of 
phosphatidylcholine (possibly the sodium adduct of PC 32:0) at m/z 756 (Figure 
5.17A), the heme group of hemoglobin at m/z 616 (Figure 5.17B) and another 
phosphatidylcholine (possibly PC 34:1) at m/z 760 (Figure 5.17C) throughout 
the control mouse lungs.
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The images show the phosphatidylcholine (PC 32:0) at m/z 756.5 is distributed 
throughout the control mouse lung tissue, whilst the phosphatidylcholine (PC 
34:1) at m/z 760.5 is primarily localised in the trachea of the control mouse lung 
tissue. The distribution of the heme of hemoglobin at m/z 616.2 shows the 
network of blood vessels throughout the control mouse lung tissue.
By changing the opacity of the distribution of a particular endogenous species in 
this case the phoshatidylcholine (PC 32:0) at m/z 756.5, the distribution of other 
species can be viewed in relation to one another. This is demonstrated in Figure 
5.17D which shows the overlaid distribution of phosphatidylcholine at m/z 756.5 
(red) and heme at m/z 616.2 (green) similarly Figure 5.17E shows the overlay of 
all three endogenous species.
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5.4. Conclusion
The work presented here describes a method for monitoring the three- 
dimensional distribution of endogenous species in the lungs of a mouse. Control 
mouse lung tissue was serially sectioned resulting in 28 tissue section obtained 
at defined intervals, these sections were individually analysed.
The addition of registration markers enabled easier 2D MALDI-MS image 
alignment and utilising Image J, software the individual 2D MALDI-MSI images 
of the distribution of a specific endogenous species were stacked together and 
viewed as a manipulate 3D image. The production of a 3D image was also 
accomplished using the Volume Explorer software.
Whilst the method requires careful sample preparation and is time consuming, 
the methodology has the potential to provide information on the 3D distribution 
of endogenous species or analytes of interest and organ substructures. 
Unfortunately a full 3D model of the lung showing the distribution of the 
endogenous species mentioned here could not be built as sections 17-21 did 
not reveal any information when analysed.
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Chapter 6
Conclusions and suggestions for future work
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6.1. Conclusions and suggestions for future work
The work reported in this thesis demonstrates the successful application of 
MALDI-MSI to monitor the distribution of respiratory compounds, used for the 
management of asthma and COPD, within lungs of preclinical species following 
inhaled delivery. Methodologies have been developed for the analysis of 
respiratory compounds that are not easily analysed by mass spectrometry. The 
generation of quantitative information from mass spectrometry images and the 
production of three-dimensional images have also been demonstrated.
MALDI-MSI has been extensively used for the analysis of pharmaceutical 
compounds. However the analysis of glucocorticoids remains a challenge as 
they contain multiple carbonyl functionalities, which are not easily 
protonated/deprotonated to form charged species under mass spectrometry 
conditions. The work presented in chapter 2 shows the successful application of 
hydrazine based reagents such as DNPH, DMNTH and Girard’s reagent P to 
solve this problem. These reagents were utilised for the in-solution and on- 
tissue derivatisation of selected glucocorticoids improving their sensitivity and 
detection by MALDI-MSI. It has also been shown that a mixture of the reactive 
matrices DNPH and DMNTH with the common MALDI matrix CHCA further 
improves the sensitivity and detection of the glucocorticoid derivatives.
Future studies in this area could be to try different derivatisation reagents such 
as ethoxyamine to form ethoxime derivatives of the glucocorticoids. Also further 
optimisation of the methodology reported, with the aim to reduce the 
derivatisation reaction time to make the ethxomine derivatisation suitable for the 
in-situ derivatisation of glucocorticoids in order monitor their distribution in the 
lungs would be useful.
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The work presented in chapter 3 relates to the main objective of this work i.e. 
detecting and monitoring the distribution of respiratory compounds in rodent 
lungs. MALDI-MSI was successfully employed on several different MS 
instruments for the screening of a range of respiratory compounds, in order to 
determine their on-tissue limit of detection.
One of the challenges with the analysis of pharmaceutical compounds by 
MALDI-MS is isobaric interference due to matrix related peaks below 500 Da. 
This was observed during the analysis of the respiratory compound Ambroxol. 
This problem could have been solved by the use of instruments with high mass 
resolving power or ion mobility separation, however in the case of this work 
careful matrix selection was used to overcome problem, negating the need for 
access to other instruments.
MALDI-MSI was employed to determine the distribution of a selected 
compound, in this case tiotropium bromide throughout the lungs following 
intratracheal delivery. The use of high spatial resolution imaging (30-50 pm) 
enabled a more detailed view of the distribution of tiotropium in the trachea and 
airways. The analysis of the lung tissue sections was performed on three 
different types of mass spectrometers enabling the results to be correlated with 
each other, good agreement was achieved. Now that reliable and reproducible 
protocols are in place further studies could be performed to determine the 
distribution of the other respiratory compounds tested in the feasibility study.
Quantitative mass spectrometry imaging is a new field that has recently gained 
a lot of attention especially in pharmaceutical research. The ability to obtain 
quantitative information as well as the distribution of pharmaceutical compounds
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and associated metabolites offers a distinct advantage over traditional 
quantitative methods such as LC-MS/MS and QWBA.
The work discussed in Chapter 4 shows the evaluation of the currently accepted 
methods for obtaining quantitative information from mass spectrometry images 
and the development of a new method.
The first method involved spotting a dilution series of tiotropium bromide onto a 
control lung tissue section, this spiked tissue section was then coated with a 
matrix containing a structural analogue (ipratropium bromide) to act as an 
internal standard. A calibration curve was produced and the addition of the 
internal standard was shown to improve the calibration curve based on the 
correlation coefficient.
The second method of quantitation involved the preparation of dilution series of 
ipratropium bromide mixed with control tissue homogenate, the homogenate 
standards were spotted onto a glass slide and analysed. The third method 
involved the preparation of homogenate standards, only this time they were 
frozen, sectioned and mounted onto a glass slide and analysed. In both cases 
the results were shown to produce a linear calibration curve.
The study led to the development of a quantitative technique for MALDI-MSI in 
the form of a homogenate standard array. This consisted of homogenate 
standards spiked with drug embedded in frozen gelatin. Sections of the array 
when cut and mounted for analysis contain all the standards necessary for the 
quantitation of pharmaceutical compounds in dosed tissue sections. Future 
work could involve the validation of the homogenate standard array method 
using traditional quantitative methods such as LC-MS/MS or QWBA. Also 
worthy of further consideration is to perform qualitative and quantitative
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experiments on respiratory compounds in the lungs following inhaled delivery 
utilising the homogenate standard array.
The use of MALDI-MS imaging has been extensively applied to monitoring the 
distribution of proteins, peptides, pharmaceutical compounds and lipids in 
biological tissues sections. This method has been expanded to analyse serial 
sections from a single specimen and can provide the three-dimensional 
distribution of endogenous species related to substructures within the tissue to 
be viewed. The work presented in Chapter 5 describes a method for generating 
a 3D image of the distribution of endogenous species throughout the lungs of a 
mouse. The tissue was serially sectioned into 28 sections at defined intervals 
and each section was individually analysed by MALDI-MSI. The addition of 
homogenate registration markers enabled easier 2D MALDI-MS image 
alignment and co-registration and utilising Image J, a freely available software 
the individual 2D MALDI-MSI images of the distribution of selected endogenous 
species were stacked together and viewed as a manipulate 3D image. The 
production of a 3D image was also accomplished using the Volume Explorer 
software. Whilst the method is time consuming and requires careful sample 
preparation, the methodology has the potential to provide information on the 3D 
distribution of endogenous species or analytes of interest within organ 
substructures. Future work in this area could be to monitor and compare the 3D 
distribution of respiratory compounds through the lung using the described 
methodology.
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